[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lung-cancer-non-small-cell\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lung-cancer-non-small-cell":24},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,31,0,25,[9,40,67,91,118,146,179,206,230,252,281,312,342,375,405,439,467,489,511,532,562,574,600,624,648],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100053514","tracking-thoracic-cancer-evolution-through-therapy-rx-evo-100053514",false,"NCT05628376","TRAcking Thoracic Cancer Evolution Through Therapy (Rx) EVO","Inclusion Criteria:\n\n* Cohort A, B and C :\n\n  * Written Informed consent\n  * Agreement to be followed up (including on-study assessments and sample collection) every 3 months in the first 2 years and then 6 monthly.\n  * Agreement to be followed up at a TRACERx EVO site\n\nCohort A:\n\n* Participants ≥18 years of age, with early stage I-IIIB NSCLC disease who are eligible for primary surgery\n* Histopathologically confirmed NSCLC, or a strong suspicion of cancer on lung imaging necessitating surgery (e.g., diagnosis determined from frozen section in theatre)\n* Primary surgery in keeping with NICE guidelines (lobectomy, either open or thoracoscopic), lung parenchymal-sparing operations (segmentectomy or wedge resection) if a complete resection can be achieved, extensive surgery (bronchoangioplastic surgery, bilobectomy, pneumonectomy) if necessary to obtain clear margins, hilar and mediastinal lymph node sampling or en bloc resection)\n* For participants proceeding with upfront primary surgery (i.e. no neoadjuvant therapy), a minimum tumour diameter of at least 15mm on imaging to allow for tissue sampling of at least two tumour regions; this can either be two fresh tissue samples or one fresh tissue sample plus one representative diagnostic FFPE block (to be requested at a later date according to trial specific procedures)\n* Participants undergoing neoadjuvant treatment must have at least 1 region of fresh frozen or FFPE surgical or diagnostic biopsy tissue.\n* Considered sufficiently fit for upfront standard of care primary surgery or neoadjuvant therapy if indicated\n* Performance status 0 to 2\n\nCohort B:\n\n* Participants ≥18 years of age, with late-stage unresectable stage IIIB and above NSCLC disease (TNM 8th edition) or presenting with stage IV de novo metastatic disease.\n* Sufficient tissue (at least 1 region\u002Fbiopsy), either FFPE or fresh frozen\n* Deemed to be fit for anti-cancer treatment\n* Performance status 0 to 2 Participants who were initially consented into Cohort A who are found to have more advanced disease pre- or immediately post operatively (e.g. locally advanced\u002Finoperable or stage IV disease) could be included in Cohort B.\n\nCohort C:\n\n* Participants ≥18 years of age, with any stage SCLC or pleural mesothelioma.\n* Sufficient tissue (at least 1 region\u002Fbiopsy), either FFPE or fresh frozen\n* Deemed to be fit for anti-cancer treatment\n* Performance status 0 to 2\n\nExclusion Criteria:\n\n* Cohort A, B and C:\n\n  * Any other active or current malignancy and\u002For systemic treatment (excluding hormone therapy) for that malignancy in the last 12 months (i.e., participant must be cancer free for the last 12 months, and if on therapy it can only be hormone therapy).\n\n    * Exceptions are: non-melanomatous skin cancer, stage 0 melanoma in situ, and in situ cervical cancer, or for Cohort C, cases of NSCLC that have transformed to SCLC, or for Cohort A another synchronous lung cancer.\n  * Psychological condition that would preclude informed consent\n  * Diagnosis other than NSCLC, SCLC or pleural mesothelioma confirmed following surgery or biopsy\n  * Confirmed diagnosis of known high-risk infections (e.g., Human Immunodeficiency Virus) (HIV), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) or syphilis infection, tuberculosis and Creutzfeldt-Jacob disease) unless participant case is of a particular scientific interest and agreed in advance with research staff, local mortuary staff and pathologist.\n  * Contra-indicated severe co-morbid conditions\n\nCohort A:\n\n* Positive margins, incomplete resection or insufficient nodal sampling\n* Insufficient tissue, i.e., for participants having upfront surgery and not having neoadjuvant therapy, a minimum of two tumour regions unlikely to be obtained for the study based on pre-operative imaging, or for participants having neoadjuvant therapy at least one tissue biopsy unable to be obtained prior to neoadjuvant therapy (Fresh Frozen or FFPE).\n* Participant found to have pre-invasive lesions rather than invasive cancer following surgery, such as adenocarcinoma in situ or minimally invasive lesions will be withdrawn. However, the surgical tissue and baseline blood already collected will be sent to the central laboratory. These participants will not be followed-up in the study or required to provide any further blood samples. If these participants subsequently develop invasive cancer, the date of diagnosis and the tumour histology will be reported on the electronic data capture system.\n\nCohort B\u002FC:\n\n• Insufficient tissue, i.e., at least one tissue biopsy unable to be obtained (Fresh Frozen or FFPE)","ALL","18 Years",{"count":19,"type":20},600,"ESTIMATED","OBSERVATIONAL","TRACERx EVO is a programme of work using a prospective observational cohort study of participants with early- and late-stage non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC) and pleural mesothelioma.",[24,25,26],"Lung Cancer, Non-small Cell","Small Cell Lung Cancer","Pleural Mesothelioma","RECRUITING","2026-07-10",{"date":30,"type":31},"2026-07-13","ACTUAL",{"date":33,"type":31},"2023-10-20",{"date":35,"type":20},"2034-06",{"name":37,"class":38},"University College, London","OTHER",1,{"id":41,"slug":42,"hasResults":12,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":47,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":66},"100610655","phase-2-a-phase-ii-study-of-skb571-in-patients-with-lung-cancer-100610655","NCT07230405","A Phase II Study of SKB571 in Patients With Lung Cancer","A Phase II Study to Evaluate the Safety and Efficacy of SKB571 in Patients With Advanced Non-small Cell Lung Cancer","Inclusion Criteria:\n\n1. Subjects aged 18-75 years at the time of signing the informed consent form\n2. Subjects with histologically or cytologically confirmed locally advanced or metastatic NSCLC .\n3. Subjects with at least one measurable lesion assessed by the investigator according to RECIST v1.1.\n4. Subjects with Eastern Cooperative Oncology Group (ECOG) status score of 0 or 1.\n5. Subjects who are assessed by the investigator to have an expected survival of ≥ 12 weeks.\n6. Subjects who have adequate organ function.\n7. Subjects who have recovered from all toxicities due to prior therapy .\n8. Male and female subjects must agree to use highly effective contraception methods during the study treatment.\n9. Subjects who voluntarily sign the informed consent form.\n\nExclusion Criteria:\n\n1. Subjects with known active or untreated central nervous system (CNS) metastases.\n2. Subjects with other malignant tumors within 3 years prior to the first dose.\n3. Subjects with history of major cardiovascular, cerebrovascular, or thromboembolic disease.\n4. Subjects with human immunodeficiency virus (HIV) infection, or any known active viral hepatitis, or hepatitis B or hepatitis C.\n5. Uncontrolled pleural effusion, pericardial effusion, or ascites effusion requiring repeated drainage.\n6. Subjects with known allergy or hypersensitivity to SKB571 or its excipients.\n7. Subjects with clinically severe lung injuries due to pulmonary complications.\n8. History of noninfectious pneumonitis\u002Finterstitial lung disease (ILD) that required steroids or has current pneumonitis\u002FILD\n9. Subjects with major surgery within 28 days prior to the first dose.\n10. Subjects who have received live vaccines within 30 days prior to the first dose of study treatment, or who are scheduled to receive live vaccines during the study.\n11. Subjects who have received strong cytochrome P450 (CYP3A4) inhibitors or inducers, or BCRP inhibitors within 2 weeks prior to the first dose of study treatment or within 5 half-lives of known drug, whichever is longer.\n12. Subjects who have received chemotherapy, immunotherapy, or biological therapy within 4 weeks prior to the first dose of study treatment.\n13. Subjects with active infection requiring systemic anti-infective therapy within 14 days prior to the first dose of study treatment.\n14. Subjects with any disease requiring systemic treatment with corticosteroids (prednisone at doses \\> 10 mg\u002Fd or similar drugs with equivalent doses) or other immunosuppressive therapy within 14 days prior to the first dose of study treatment.\n15. Any condition that, in the opinion of the investigator, will interfere with the assessment of study treatment or the safety of the subject or the interpretation of the study results.","75 Years",{"count":49,"type":20},295,"INTERVENTIONAL",[52],"PHASE2","This is a multicenter, phase II study. The purpose of this study is to evaluate the safety and preliminary anti-tumor activity of SKB571 in patients with advanced non-small cell lung cancer. Eligible subjects will receive SKB571 monotherapy, until radiographic disease progression, intolerable toxicity, discontinuation of study treatment required by the subject, or other protocol-specified treatment discontinuation criteria, whichever occurs first.",[55],"Lung Cancer (Non-Small Cell)","2026-05-10",{"date":58,"type":31},"2026-05-12",{"date":60,"type":31},"2026-01-19",{"date":62,"type":20},"2028-01-19",{"name":64,"class":65},"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","INDUSTRY",2,{"id":68,"slug":69,"hasResults":12,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":75,"targetDuration":77,"studyType":21,"phases":4,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":87,"leadSponsor":89,"locationsCount":39},"100636121","feasibility-and-effectiveness-of-respiratory-movement-management-in-lung-cancer-receiving-stereotactic-radiotherapy-using-a-novel-positional-fixation-device-100636121","NCT07561567","Feasibility and Effectiveness of Respiratory Movement Management in Lung Cancer Receiving Stereotactic Radiotherapy Using a Novel Positional Fixation Device","A Single Center, Translational Study on the Feasibility and Effectiveness of Respiratory Movement Management in Lung Cancer Patients Receiving Stereotactic Radiotherapy Using a Novel Positional Fixation Device","E20241186","Inclusion Criteria:\n\nClinical diagnosis is solitary peripheral lung cancer, and after comprehensive evaluation by the participating physicians based on the patient's clinical data, it is suitable for receiving SBRT treatment;\n\nExclusion Criteria:\n\nCentral or super central lung cancer patients who are intolerant or unwilling to undergo respiratory suppression and chest and abdominal compression fixation",{"count":76,"type":20},50,"1 Year","The purpose of this clinical trial is to understand the safety and effectiveness of abdominal pressure devices in inhibiting respiratory movement in lung cancer patients. The main question it aims to answer is:\n\nDid the abdominal pressure device reduce the respiratory movement of participants with lung cancer tumors?\n\nParticipants will:\n\nRecord how much they use abdominal pressure devices to suppress lung cancer tumor respiratory movement",[80],"Lung Cancer, Non-Small Cell",[82],"Respiratory Movement Management","2026-04-24",{"date":85,"type":31},"2026-05-01",{"date":56,"type":20},{"date":88,"type":20},"2026-12-31",{"name":90,"class":38},"Tianjin Medical University Cancer Institute and Hospital",{"id":92,"slug":93,"hasResults":12,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":100,"conditions":101,"keywords":102,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":117},"100568913","sleeve-lobectomy-for-lung-cancer-in-minimally-invasive-surgical-techniques-100568913","NCT06687408","Sleeve Lobectomy for Lung Cancer in Minimally Invasive Surgical Techniques","Sleeve Lobectomy for Lung Cancer in Minimally Invasive Surgical Techniques: a Multicenter Cohort Study","Inclusion Criteria:\n\n* Age ≥ 18 years;\n* Clinically suspected lung cancer with a high likelihood of undergoing sleeve lobectomy;\n* Postoperative histopathological diagnosis confirms non-small cell lung cancer (NSCLC);\n* No history of malignancy within the past 5 years;\n* Signed informed consent agreeing to participate in this study.\n\nExclusion Criteria:\n\n* Unable to undergo surgical resection due to surgical contraindications;\n* Postoperative pathology does not confirm non-small cell lung cancer (NSCLC), including but not limited to benign lesions, small cell lung cancer, metastatic tumors, or an insufficient or indeterminate histopathology report;\n* History of malignancy within the past 5 years;\n* Unable to obtain follow-up data;\n* Refusal to sign the informed consent or withdrawal of consent.",{"count":99,"type":20},450,"The goal of this multicenter observational study is to evaluate the long-term survival and perioperative outcomes of sleeve lobectomy in robotic-assisted thoracic surgery (RATS) for patients with central lung cancer when compared with video-assisted thoracic surgery (VATS) approach, both of which have been already applied to these patients in minimally invasive surgical techniques as part of their regular medical care recently. The main question it aims to answer is:\n\nAre RATS sleeve lobectomy associated with similar or even better long-term survival and perioperative outcomes for patients with central lung cancer when compared with the VATS approach?",[80],[103,104,105,106,107,108],"lung cancer","sleeve lobectomy","minimally invasive thoracic surgery","perioperative outcomes","long-term survival","robotic-assisted thoracic surgery","2026-04-21",{"date":83,"type":31},{"date":112,"type":31},"2025-03-01",{"date":114,"type":20},"2027-12-31",{"name":116,"class":38},"Second Affiliated Hospital, School of Medicine, Zhejiang University",3,{"id":119,"slug":120,"hasResults":12,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":127,"conditions":128,"keywords":131,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":39},"100631415","multimodal-nutritional-and-sarcopenia-assessment-for-risk-stratification-in-lung-cancer-surgery-100631415","NCT07500376","Multimodal Nutritional and Sarcopenia Assessment for Risk Stratification in Lung Cancer Surgery","Prognostic Value of Multimodal Nutritional Status and Sarcopenia Assessment for Postoperative Risk Stratification in Patients Undergoing Lung Cancer Surgery: A Prospective Cohort Study","Inclusion Criteria:\n\n* Age ≥18 years\n* Patients undergoing anatomical lung resection (lobectomy or segmentectomy) for primary lung cancer\n* Availability of preoperative thoracic computed tomography (CT) within 30 days before surgery\n* Completion of preoperative nutritional assessment and ultrasonographic muscle measurements\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Receipt of neoadjuvant chemotherapy, immunotherapy, or radiotherapy\n* Emergency surgery\n* Pneumonectomy\n* Combined resection of another organ during the same procedure\n* Inadequate or non-evaluable imaging or measurement data\n* Immunosuppressive therapy or presence of advanced\u002Fmetastatic disease\n* Significant thoracic deformity or prior conditions interfering with muscle measurements\n* Refusal or inability to provide informed consent",{"count":126,"type":20},142,"This prospective observational cohort study aims to evaluate the prognostic value of multimodal nutritional status and sarcopenia assessment in patients undergoing lung cancer surgery. Postoperative complications, mortality, and prolonged hospital stay remain major clinical concerns in thoracic surgery. Although malnutrition and sarcopenia are recognized as important determinants of surgical outcomes, their combined and multidimensional evaluation has not been sufficiently studied.\n\nAdult patients undergoing anatomical lung resection for primary lung cancer will be included. Nutritional status will be assessed using serum biomarkers, inflammatory indices, and validated clinical nutritional scores. Sarcopenia will be evaluated using computed tomography-based muscle mass and density measurements, as well as ultrasonographic muscle thickness.\n\nThese parameters will be analyzed in relation to postoperative complications, intensive care unit (ICU) requirement, length of hospital stay, and mortality. Multivariable analyses will be performed to identify independent predictors, and a combined risk stratification model will be developed.\n\nThis study aims to improve preoperative risk assessment and to support personalized perioperative management strategies, including identification of patients who may benefit from targeted nutritional optimization and prehabilitation.",[55,129,130],"Sarcopenia","Malnutrition Severe",[132,133,134,135,136],"lung cancer surgery","sarcopenia","nutritional status","malnutrition","risk stratification","2026-03-24",{"date":139,"type":31},"2026-03-30",{"date":141,"type":31},"2026-03-15",{"date":143,"type":20},"2026-07-15",{"name":145,"class":38},"Ondokuz Mayıs University",{"id":147,"slug":148,"hasResults":12,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":152,"eligibilityCriteria":153,"healthyVolunteers":12,"sex":16,"minAge":154,"maxAge":155,"enrollmentInfo":156,"targetDuration":4,"studyType":50,"phases":158,"briefSummary":160,"conditions":161,"keywords":167,"overallStatus":170,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":117},"100631613","effectiveness-of-a-multimodal-outpatient-supervised-physical-activity-program-to-improve-tolerance-and-efficacy-of-chemotherapy-in-adults-with-breast-lung-and-colon-cancer-100631613","NCT07502963","Effectiveness of a Multimodal Outpatient Supervised Physical Activity Program to Improve Tolerance and Efficacy of Chemotherapy in Adults With Breast, Lung and Colon Cancer","Effectiveness of a Multimodal Outpatient Supervised Physical Activity Program to Improve Tolerance and Efficacy of Chemotherapy in Adults With Breast, Lung and Colon Cancer: Randomized Clinical Trial.","PREDU","Inclusion Criteria:\n\n* Women and men aged 35 to 65 years\n* Diagnosed with stage II, III, or IV breast, lung, or colon cancer\n* Scheduled to start neoadjuvant chemotherapy\n* Able and willing to provide written informed consent\n\nExclusion Criteria:\n\n* Musculoskeletal or neurological disorders that prevent proper execution of the exercises\n* Uncontrolled infections or symptoms\n* Comorbidities such as chronic obstructive pulmonary disease (COPD), respiratory failure, or recent cardiovascular events within the past 6 months\n* Body mass index (BMI) over 35\n* Pregnant women\n* Difficulty understanding the purpose and procedures of the study","35 Years","65 Years",{"count":157,"type":20},70,[159],"NA","This clinical study evaluates whether a supervised, multimodal therapeutic exercise program started before chemotherapy and continued during treatment can improve treatment outcomes in patients aged 35 to 65 years with breast, lung, or colon cancer.\n\nThe study hypothesis is that participation in this exercise program improves tolerance to chemotherapy, allowing patients to receive more than 85% of the planned relative dose intensity. In addition, the program is expected to enhance treatment effectiveness by increasing the rate of complete radiological response.\n\nThe main objective of the study is to assess the effectiveness of a supervised, multimodal therapeutic exercise program performed before and during chemotherapy in improving both treatment tolerance and treatment efficacy in patients with breast, lung, and colon cancer.",[162,55,163,164,165,166],"Breast Cancer","Colorectal Cancer","Physical Activity","Neoadjuvant Chemotherapy Tolerance","Strength and Endurance",[162,55,168,164,169,165],"Colorectal cancer","Strength and endurance","NOT_YET_RECRUITING",{"date":172,"type":31},"2026-03-31",{"date":174,"type":20},"2026-04",{"date":176,"type":20},"2027-10",{"name":178,"class":38},"University of Vic - Central University of Catalonia",{"id":180,"slug":181,"hasResults":12,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":185,"eligibilityCriteria":186,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":187,"targetDuration":4,"studyType":50,"phases":189,"briefSummary":191,"conditions":192,"keywords":195,"overallStatus":170,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":66},"100630359","phase-1-osimertinib-plus-capivasertib-in-nsclc-with-pik3caakt1pten-alterations-following-prior-1l-osimertinib-100630359","NCT07486648","Osimertinib Plus Capivasertib in NSCLC With PIK3CA\u002FAKT1\u002FPTEN Alterations Following Prior 1L Osimertinib","The Safety and Efficacy of Osimertinib Plus Capivasertib in EGFRm Advanced Non-small Cell Lung Cancer (NSCLC) Participants With PIK3CA\u002FAKT1\u002FPTEN Alterations Who Had Progressed on First-line Osimertinib Monotherapy or Plus Chemotherapy: a First-in-human, Phase Ib\u002FⅡa Study (PRECISION)","Precision","Inclusion criteria\n\nInformed consent\n\n1. Provision of signed and dated, written informed consent form (ICF) prior to any mandatory and non-mandatory study-specific procedures, sampling and analyses\n\n   Age\n2. Male or female age ≥18 years at the time of signing the ICF.\n\n   Type of participant and disease characteristics\n3. Histologically or cytologically confirmed non-squamous locally advanced or metastatic NSCLC which is not amenable to curative therapy.\n4. Documented EGFR sensitive mutations (exon19 deletion, L858R mutation) prior to the first-line EGFR-TKI therapy.\n5. Documented radiologic progression on first-line treatment with Osimertinib monotherapy or Osimertinib plus chemotherapy:\n\n   * Participants treated with Osimertinib in the adjuvant setting can be included if progression occurred \\\u003C 6 months after last dose.\n   * Participants must be immunotherapy (i.e., programmed cell death protein 1 \\[PD-1\\] inhibitor, programmed cell death protein 1 ligand 1 \\[PD-L1\\] inhibitor, Cytotoxic T-lymphocyte associated protein 4 inhibitor) naïve in the metastatic setting.\n   * Prior immunotherapy in the neoadjuvant or adjuvant setting is acceptable providing treatment was completed more than 6 months before metastatic\u002Frecurrent disease was diagnosed.\n6. Mandatory provision of the required number of FFPE tumour tissue samples for PIK3CA mutations and\u002For AKT1 mutations and\u002For PTEN loss-of-function (LOF) mutations testing, which fulfils the following requirements:\n\n   * Obtained following progression on previous Osimertinib monotherapy or Osimertinib plus chemotherapy as first-line treatment.\n   * Specimen to meet the requirements defined in the Central Laboratory Manual and Diagnostic Testing Manual.\n   * Have PIK3CA and\u002For AKT1 and\u002For PTEN alterations as determined by NGS testing by a sponsor designated central laboratory on tumour specimen collected following progression on prior Osimertinib treatment.\n7. At least one lesion, not previously irradiated, not biopsied during the screening period, that can be accurately measured at baseline as ≥ 10 mm in the longest diameter (except lymph nodes which must have short axis ≥ 15 mm) with CT or MRI, which is suitable for accurate repeated measurements. If only one measurable lesion exists, it is acceptable to be used if baseline tumour assessment scans are done at least 14 days after the screening tumour specimen collection is performed.\n8. Adequate bone marrow reserve and organ function as follows:\n\n   * Absolute neutrophils count (ANC) ≥1.5x109\u002FL.\n   * Platelets count ≥100x109\u002FL.\n   * Haemoglobin (Hb) ≥90g\u002FL.\n   * Total bilirubin ≤1.5 times upper limit of normal (ULN) or ≤3 times ULN in the presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinaemia) or liver metastases.\n   * Alanine transaminase (ALT) and aspartate transaminase (AST) ≤2.5ULN (or ≤5 ULN in the presence of liver metastases).\n   * Serum Creatinine ≤1.5 ULN or creatinine clearance (CCr) ≥50mL\u002Fmin (measured or calculated by Cockcroft and Gault equation); confirmation of creatinine clearance is only required when creatinine is \\>1.5 times ULN.\n9. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n10. Patients with hepatitis B virus (HBV) are only eligible for inclusion if they meet all the following criteria:\n\n    * Demonstrated absence of hepatitis C virus (HCV) co-infection or history of HCV co-infection\n    * Demonstrated absence of human immunodeficiency virus (HIV) infection\n    * Participants with active HBV infection are eligible if they are:\n    * Receiving anti-viral treatment for at least 6 weeks prior to study treatment, HBV DNA is suppressed to \\\u003C100 IU\u002FmL and transaminase levels are below ULN.\n    * Participants with a resolved or chronic HBV infection are eligible if they are:\n    * Negative for HBsAg and positive for hepatitis B core antibody \\[anti-HBc IgG or total anti-HBc Ab\\]. In addition, patients should be referred to a local hepatologist and treated as per local guidelines.\n\n    or\n\n    • Positive for HBsAg, but for \\> 6 months have had transaminases levels below ULN and HBV DNA levels below \\\u003C100 IU\u002FmL or below the detectable limit of locally available test kit (i.e., are in an inactive carrier state). In addition, patients must be receiving anti-viral prophylaxis for 2-4 weeks prior to study treatment.\n\n    Patients with HIV are only eligible for inclusion if they meet all the following criteria:\n    * Demonstrated absence of HBV\u002F HCV co-infection\n    * Undetectable viral RNA load for 6 months\n    * CD4+ count of \\>350 cells\u002FµL\n    * No history of AIDS-defining opportunistic infection within the past 12 months\n\n    Stable for at least 4 weeks on the same anti-HIV medications.\n11. Ability to swallow and retain oral medications.\n12. Willingness and ability to comply with study and follow-up procedures. Reproduction\n13. Females must be using highly effective contraceptive measures, and must have a negative pregnancy test prior to start of dosing if of child-bearing potential, or must have evidence of non-child-bearing potential by fulfilling one of the following criteria at screening:\n\n    * Post-menopausal defined as aged 50 years or more and amenorrhoeic for at least 12 months following cessation of all exogenous hormonal treatments.\n    * Women under 50 years old would be considered postmenopausal if they have been amenorrhoeic for 12 months or more following cessation of exogenous hormonal treatments and with LH and FSH levels in the post-menopausal range for the institution.\n    * Documentation of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation.\n\n    Further information in Appendix C (Definition of Women of Childbearing Potential and Acceptable Contraceptive Methods).\n14. Male participants must be willing to use barrier contraception. Exclusion criteria\n\nMedical conditions\n\n1. Patients harbouring concurrent actionable driver mutations with locally approved targeted therapies (e.g., MET amplification) will be excluded.\n2. Past medical history of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active ILD.\n3. Clinically significant abnormalities of glucose metabolism as defined by any of the following:\n\n   * Fasting glucose ≥7.0 mmol\u002FL (126 mg\u002FdL) or 2 hours after glucose solution intake, blood glucose ≥11.1 mmol\u002FL (200 mg\u002FdL).\n   * HbA1c ≥8.0% (63.9 mmol\u002Fmol) at screening. Note: for any patient with evidence of impaired glucose control or insulin resistance refer to the Capivasertib Toxicity Management Guidelines.\n4. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses, which in the investigator's opinion makes it undesirable for the patient to participate in the trial or which would jeopardize compliance with the protocol, or active infection (e.g. patients receiving treatment for infection) including hepatitis C and human immunodeficiency virus (HIV), or active uncontrolled hepatitis B virus (HBV) infection, or active tuberculosis infection (clinical evaluation that may include clinical history, physical examination and radiographic findings, or tuberculosis testing in line with local practice) .\n\n   • Screening for chronic conditions is not required.\n5. Spinal cord compression, leptomeningeal metastasis, or brain metastases unless asymptomatic, stable, and not requiring steroids for at least 4 weeks prior to start of study intervention.\n6. Any of the following cardiac criteria:\n\n   * Mean resting corrected QTc \\>470 msec, obtained from triplicate electrocardiograms (ECGs), using the screening clinic ECG machine derived QTc value.\n   * History of QT prolongation associated with other medications that required discontinuation of that medication.\n   * Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG e.g., complete left bundle branch block, third degree heart block and second-degree heart block.\n   * Medical history significant for arrhythmia (e.g., multifocal premature ventricular contractions, bigeminy, trigeminy, ventricular tachycardia), which is symptomatic or requires treatment (Common Terminology Criteria for Adverse Events \\[CTCAE\\] Grade 3), symptomatic or uncontrolled atrial fibrillation despite treatment, or asymptomatic sustained ventricular tachycardia. Participants with atrial fibrillation controlled by medication or arrhythmias controlled by pacemakers may be permitted to enter the study based on the Investigator judgement with cardiologist consultation recommended.\n   * Patient with any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as electrolyte abnormalities including:\n\n     * Hypokalaemia\\|\\* ≥ CTCAE Grade 2.\n     * Heart failure, congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death under 40 years of age in first-degree relatives or any concomitant medication known to prolong the QT interval and cause Torsade de Pointes.\n     * Correction of electrolyte abnormalities should be documented prior to first dose.\n   * Experience of any of the following procedures or conditions in the preceding 6 months: coronary artery bypass graft, angioplasty, vascular stent, myocardial infarction, angina pectoris, congestive heart failure New York Heart Association (NYHA) Grade 2.\n7. History of another primary malignancy except for malignancy treated with curative intent with no known active disease ≥2 years before the first dose of investigational product (IP) and of low potential risk for recurrence. Exceptions include adequately resected non-melanoma skin cancer and curatively treated in situ disease.\n8. Any unresolved toxicities from prior therapy greater than CTCAE grade 1 at the time of starting study treatment except for alopecia and grade 2 prior platinum-therapy related neuropathy. Participants with irreversible toxicity that is not reasonably expected to be exacerbated by study intervention in the opinion of the Investigator may be included (e.g., hearing loss).\n9. Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption, distribution, metabolism, or excretion of IP.\n10. Any other disease, physical examination finding, or clinical laboratory finding that, in the investigator's opinion, gives reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug, may affect the interpretation of the results, render the patient at high risk from treatment complications or interferes with obtaining informed consent.\n\n    Prior\u002Fconcomitant therapy\n11. Prior or current treatment with a third-generation EGFR-TKI other than Osimertinib.\n12. Prior or current treatment with any PI3K\u002FAKT pathway inhibitors, including but not limited to: Capivasertib or other AKT inhibitors, PI3K inhibitors, or agents targeting key nodes in this pathway (e.g., PTEN-modulating therapies).\n13. Concurrent use of herbal or natural products intended as treatment or prophylaxis for any type of cancer.\n14. Wide field radiotherapy (including therapeutic radioisotopes such as strontium 89) administered ≤ 28 days or limited field radiation for palliation ≤ 14 days prior to starting study intervention or has not recovered from side effects of such therapy.\n15. Major surgery or significant traumatic injury within 4 weeks of the first dose of study intervention or an anticipated need for major surgery during the study. Procedures such as placement of vascular access, biopsy via mediastinoscopy or biopsy via video assisted thoracoscopic surgery (VATS) are permitted.\n16. Systemic therapy: Prior exposure to any anti-cancer agents other than those specified in the protocol (e.g. hormonal therapy such as luteinizing hormone releasing hormone \\[LHRH\\] agonists) without appropriate washout period before enrolment, for example, enrolment within 3 half-lives of a small molecule anti-cancer agent, or within 4 weeks for any antibody-based anticancer agents.\n17. Participants currently receiving (or unable to stop use prior to receiving the first dose of study treatment) medications or herbal supplements known to be strong inducers (at least 3-week prior), moderate inducers (at least 2-week prior) or strong inhibitors of CYP3A4 (at least 2-week prior). All participants must try to avoid concomitant use of any medications, herbal supplements and\u002For ingestion of foods with known inducer or inhibitor effects on CYP3A4. Any concomitant medication that may interfere with Osimertinib safety and efficacy based on the prescribing information of Osimertinib and local clinical guidelines.\n\n    Prior\u002Fconcurrent clinical study experience\n18. Participation in another clinical study with a study intervention or investigational medicinal device administered in the 4 weeks prior to first dose of study intervention or concurrent enrolment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study.\n\n    Other exclusions\n19. History of hypersensitivity to active or inactive excipients of Capivasertib or Osimertinib or drugs with a similar chemical structure or class.\n20. Women who are currently pregnant (confirmed with positive pregnancy test) or breast-feeding or planning to become pregnant.\n21. Involvement in the planning and\u002For conduct of the study (applies to both Investigator staff and\u002For staff at the study site).",{"count":188,"type":20},53,[190,52],"PHASE1","The goal of this clinical trial is to learn if Osimertinib plus Capivasertib works to treat EGFRm advanced non-small cell lung cancer (NSCLC) in participants with PIK3CA\u002FAKT1\u002FPTEN alterations after progression on first-line Osimertinib (monotherapy or plus chemotherapy).\n\nThe main questions it aims to answer are:\n\nPart A:\n\n* Number of Dose-limiting toxicities (DLTs)\n* Adverse events (AEs)\u002Fserious adverse events (SAEs) (graded by CTCAE Version 5.0)\n* Recommended combined dose (RCD)\n\nPart B:Confirmed ORR assessed by the Investigator per RECIST 1.1 criteria.\n\nParticipants will:\n\nPart A:Take Capivasertib twice daily from day 1 to 4 of a 7-day cycle, Osimertinib will be given orally QD(once daily) at 80 mg throughout the study treatment period.\n\nPart B: Take Osimertinib (80mg QD, continuously) and Capivasertib(RCD,orally BID from day1-day 4 in 7-day cycle , 4 days on \u002F3 days off) till disease progression (PD) or unacceptable toxicity.",[193,55,194],"Lung Cancer (NSCLC)","Advanced Non-small-cell Lung Cancer",[196,197],"NSCLC","Osimertinib plus Capivasertib","2026-03-23",{"date":137,"type":31},{"date":201,"type":20},"2026-05-15",{"date":203,"type":20},"2028-12-31",{"name":205,"class":38},"Shanxi Province Cancer Hospital",{"id":207,"slug":208,"hasResults":12,"nctId":209,"briefTitle":210,"officialTitle":210,"acronym":211,"eligibilityCriteria":212,"healthyVolunteers":213,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":214,"targetDuration":4,"studyType":50,"phases":215,"briefSummary":216,"conditions":217,"keywords":218,"overallStatus":170,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":226,"leadSponsor":228,"locationsCount":39},"100605514","immune-response-to-immunotherapy-in-lung-cancer-study-of-sputum-and-blood-samples-100605514","NCT07163507","Immune Response to Immunotherapy in Lung Cancer: Study of Sputum and Blood Samples","RICEPS-2","Inclusion Criteria:\n\n. Age 18 years or older\n\n* Diagnosis of locally advanced or metastatic non-small cell lung cancer (NSCLC)\n* Requiring initiation of treatment with anti-PD1 or anti-PDL1 ICI (nivolumab, pembrolizumab, atezolizumab, durvalumab, cemiplimab), with or without chemotherapy\n* Never having received ICI treatment\n* Affiliated with a social security system\n* Having signed a written, free, and informed consent form\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women\n* Individuals under guardianship, conservatorship, or judicial protection, or in a situation of deprivation of liberty",true,{"count":76,"type":20},[159],"Lung cancer is the leading cause of cancer-related death worldwide, with nearly 2.48 million cases and 1.8 million deaths in 2022. Despite therapeutic progress, late diagnosis and high mortality make it a major public health issue. Immune checkpoint inhibitors (ICI) such as nivolumab, pembrolizumab, and atezolizumab have improved outcomes for some patients, but only a small proportion benefit, and side effects can be severe. Research is focusing on combining ICIs with chemotherapy, radiotherapy, or other immunotherapies, but reliable biomarkers to predict responders are still lacking. The tumor microenvironment, which promotes resistance, is a promising therapeutic target. The RICEPS study (2021-2023) found specific immune cells and cytokines linked to treatment response, and the ongoing RICEPS-2 trial aims to confirm these findings in a larger group to better understand immune dynamics in lung cancer under ICI therapy.",[193,55],[219,220,221],"immunotherapy","sputum samples","blood samples","2026-03-17",{"date":224,"type":31},"2026-03-18",{"date":174,"type":20},{"date":227,"type":20},"2028-10",{"name":229,"class":38},"University Hospital, Tours",{"id":231,"slug":232,"hasResults":12,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":4,"eligibilityCriteria":236,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":47,"enrollmentInfo":237,"targetDuration":4,"studyType":50,"phases":239,"briefSummary":240,"conditions":241,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":251},"100608229","phase-2-ibi351-plus-cetuximab--in-untreated-advanced-non-small-cell-lung-cancer-with-kras-g12c-mutation-100608229","NCT07198841","IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation","The Efficacy and Safety of IBI351 Plus Cetuximab β in Untreated, Locally Advanced or Metastatic Non-small Cell Lung Cancer With KRAS G12C Mutation: A Single-arm, Prospective, Multicenter Phase II Clinical Study","Inclusion Criteria\n\n1. Voluntarily participate in the study and sign the informed consent form (ICF).\n2. Male or female subjects aged ≥18 years and ≤75 years at the time of signing the ICF.\n3. Life expectancy ≥ 3 months.\n4. Histologically or cytologically confirmed unresectable locally advanced (Stage IIIB\u002FIIIC), metastatic, or recurrent (Stage IV) non-small cell lung cancer (NSCLC), per the International Association for the Study of Lung Cancer (IASLC) and American Joint Committee on Cancer (AJCC) 8th edition TNM staging, and not candidates for curative concurrent chemoradiotherapy.\n5. Documented KRAS G12C mutation confirmed by a written report from a certified laboratory.\n6. Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1.\n7. No prior systemic anti-tumor therapy for locally advanced or metastatic non-squamous NSCLC. Subjects who received prior adjuvant therapy are eligible provided disease recurrence occurred ≥6 months after the last dose of adjuvant therapy or the last session of radical radiotherapy.\n8. At least one measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Lesions within a prior radiation field or after local therapy can be considered target lesions if documented progression is evident.\n9. Adequate organ and bone marrow function, defined as:\n\n1）Hematopoietic: Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹\u002FL, platelet count ≥ 100 × 10⁹\u002FL, hemoglobin ≥ 9 g\u002FdL. No transfusion or treatment with granulocyte colony-stimulating factor (G-CSF), thrombopoietin, or erythropoietin within 14 days prior to hematology tests.\n\n2）Hepatic: Total bilirubin (TBIL) \\\u003C 1.5 × upper limit of normal (ULN), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \\\u003C 2.5 × ULN. For subjects with Gilbert's syndrome, TBIL \\\u003C 2 × ULN is acceptable. For subjects with liver metastases, AST and ALT \\\u003C 5.0 × ULN is required. If direct bilirubin (DBIL) suggests extrahepatic obstruction, TBIL \\\u003C 3.0 × ULN is permitted.\n\n3）Renal: Serum creatinine (Cr) ≤ 1.5 × ULN OR calculated creatinine clearance (CrCl) ≥ 60 mL\u002Fmin (using the Cockcroft-Gault formula) if Cr \\> 1.5 × ULN.\n\n4）Coagulation: Prothrombin time (PT) \u002F activated partial thromboplastin time (APTT) \\\u003C 1.5 × ULN and international normalized ratio (INR) \\\u003C 1.5 or within the therapeutic range for subjects on anticoagulation therapy.\n\n5）Magnesium: Serum magnesium within normal limits. 10. Toxicities from prior anti-tumor therapy must have resolved to baseline or ≤ Grade 1 (except for residual alopecia; neurotoxicity ≤ Grade 2 is acceptable). Subjects with prior immune-related endocrine adverse events (irAEs) from immunotherapy (e.g., hypothyroidism) that are asymptomatic and stably controlled with ongoing hormone replacement or physiologic doses of corticosteroids may be enrolled if the investigator judges that this will not affect study drug administration or safety assessment.\n\n11\\. Female subjects of childbearing potential or male subjects with partners of childbearing potential must use effective contraception from signing the ICF until 6 months after the last dose of study drug. Female subjects of childbearing potential must have a negative serum pregnancy test within 7 days (inclusive) prior to the first dose. If a urine pregnancy test result is inconclusive, a serum pregnancy test is required.\n\nExclusion Criteria\n\n1. Histologically or cytologically confirmed NSCLC with mixed small cell components or predominantly squamous cell carcinoma components.\n2. Presence of EGFR sensitizing mutation, ALK rearrangement, ROS-1 fusion, or other genomic alterations for which NMPA-approved first-line NSCLC therapies exist.\n3. Significant cardiovascular or cerebrovascular disease, including:\n\n1）Clinically significant cardiovascular events within 6 months (e.g., myocardial infarction, angina, heart failure, severe arrhythmia) or history of angioplasty, stenting, or coronary artery bypass grafting.\n\n2）Clinically significant prolongation of the QTcF interval (QTcF \\> 470 ms for females or \\> 450 ms for males).\n\n3）Clinically significant cerebrovascular events within 3 months (e.g., cerebral hemorrhage, infarction).\n\n4\\. Active central nervous system (CNS) metastases (e.g., brain or leptomeningeal metastases). Subjects with previously treated brain metastases may be eligible if they are asymptomatic for at least 7 days after completion of radiotherapy\u002Flocal therapy without requiring steroids\u002Fanti-epileptics, OR off steroids\u002Fanti-epileptics for at least 7 days, AND judged by the investigator to have stable CNS disease.\n\n5\\. Clinically significant interstitial lung disease (ILD), radiation pneumonitis, or drug-induced pneumonitis requiring treatment; active pulmonary tuberculosis; pneumoconiosis; Grade ≥2 pneumonitis of other etiologies; or severely impaired pulmonary function (FEV1 or DLCO or DLCO\u002FVA \\\u003C40% of predicted value).\n\n6\\. Significant gastrointestinal disorders affecting drug absorption or swallowing (e.g., refractory hiccups, nausea, vomiting, severe peptic ulcer disease, liver cirrhosis, active GI bleeding).\n\n7\\. Major active or chronic infections, including:\n\n1. Active infection requiring systemic therapy.\n2. Baseline positive HIV antibody (HIV-Ab); acute or chronic active hepatitis B (defined as HBsAg and\u002For HBcAb positive AND HBV-DNA \\> 2500 copies\u002FmL or 500 IU\u002FmL); or acute or chronic active hepatitis C (HCV antibody positive AND HCV-RNA above the lower limit of quantification).\n3. Active pulmonary tuberculosis. 8. Symptomatic pleural, peritoneal, or pericardial effusions requiring repeated drainage.\n\n9\\. Poorly controlled systemic diseases despite standard therapy (e.g., hypertension: systolic BP ≥160 mmHg or diastolic BP ≥100 mmHg; diabetes).\n\n10\\. History of other active malignancies within 2 years prior to study entry, except appropriately treated carcinoma in situ of the cervix, localized squamous cell carcinoma of the skin, basal cell carcinoma, prostate cancer not requiring treatment, ductal carcinoma in situ of the breast, and superficial non-muscle invasive urothelial carcinoma.\n\n11\\. Prior treatment with any KRAS G12C inhibitor. 12. Prior treatment with cetuximab or its analogues. 13. Systemic treatment with Chinese herbal medicine with anti-tumor indications within 1 week prior to the first dose, OR systemic treatment with immunomodulatory drugs (including thymosin, interferon, interleukin; except for localized intrapleural use for effusion control) within 2 weeks prior to the first dose.\n\n14\\. Therapeutic or palliative radiotherapy (except cranial radiotherapy) or local therapy within 14 days prior to the first study dose.\n\n15\\. Any other anti-tumor therapy (chemotherapy, targeted therapy, immunotherapy, investigational drug\u002Fdevice) within 28 days or 5 half-lives (whichever is shorter) prior to the first study dose.\n\n16\\. Major surgery within 28 days prior to study entry that could affect study drug administration or assessments (excluding diagnostic biopsy).\n\n17\\. Use of known sensitive substrates of CYP2D6, CYP3A4, P-gp, or BCRP with a narrow therapeutic window within 14 days or 5 half-lives (whichever is longer) prior to the first study dose, unless agreed upon by both the investigator and sponsor.\n\n18\\. Concurrent participation in another interventional clinical trial (participation in observational studies or the follow-up phase of an interventional study is permitted).\n\n19\\. Use of immunosuppressive drugs within 4 weeks prior to the first study dose, excluding intranasal, inhaled, or topical corticosteroids; systemic corticosteroids at physiologic doses (≤10 mg\u002Fday prednisone or equivalent); or corticosteroids administered for prophylaxis of contrast media allergy.\n\n20\\. Administration of live attenuated vaccines within 4 weeks prior to the first study dose or planned during the study period.\n\nNote: Inactivated seasonal influenza vaccines administered \\>4 weeks prior are allowed; live attenuated influenza vaccines are not permitted.\n\n21\\. Known or suspected autoimmune disease, or history of autoimmune disease within 2 years prior to screening (subjects with vitiligo, psoriasis, alopecia, or Graves' disease not requiring systemic therapy in the last 2 years, hypothyroidism managed only with hormone replacement, or type 1 diabetes managed only with insulin replacement are eligible).\n\n22\\. Known history of primary immunodeficiency. 23. History of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.\n\n24\\. History of deep vein thrombosis, pulmonary embolism, or any other severe thromboembolic event within 3 months prior to enrollment (implant port- or catheter-related thrombosis, or superficial venous thrombosis are not considered \"severe\").\n\n25\\. Known hypersensitivity to any component of the study drug or its formulation.\n\n26\\. Pregnant or breastfeeding women. 27. Any other condition that, in the investigator's judgment, would make the subject unsuitable for participation in the study.",{"count":238,"type":20},48,[52],"Study Design: a Phase II, single-arm, multicenter, prospective, interventional study.\n\nTarget Population: Subjects with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) confirmed to harbor the KRAS G12C mutation.\n\nTreatment Regimen: All enrolled subjects will receive IBI351 combined with cetuximab β injection. Treatment will continue until disease progression (as assessed by the investigator per RECIST 1.1 criteria) or the occurrence of intolerable toxicity.\n\nPrimary Endpoint: Objective Response Rate (ORR) as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.\n\nSecondary Endpoints: Disease Control Rate (DCR), Time to Response (TTR), Progression-Free Survival (PFS), and Overall Survival (OS) , and safety.",[55],"2026-03-08",{"date":244,"type":31},"2026-03-11",{"date":246,"type":31},"2025-11-03",{"date":248,"type":20},"2028-09",{"name":250,"class":38},"Guangdong Association of Clinical Trials",7,{"id":253,"slug":254,"hasResults":12,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":258,"eligibilityCriteria":259,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":260,"targetDuration":4,"studyType":50,"phases":262,"briefSummary":263,"conditions":264,"keywords":269,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":39},"100609797","engagement-of-veterans-with-lung-cancer-100609797","NCT07219251","Engagement of Veterans With Lung Cancer","Engagement of Veterans With Lung Cancer (EVLC)","EVLC","Inclusion Criteria:\n\n1. Veteran patients with diagnosis of any stage of lung cancer;\n2. 18 years of age or older;\n3. English- or Spanish-speaking;\n4. can self-administer questionnaires in English or Spanish;\n5. valid telephone number;\n6. receiving oncology care at participating sites;\n7. currently newly diagnosed or receiving or having completed systemic anti-cancer therapy and\u002For radiation therapy within 12 months, defined as oral, injection, or intravenous therapy (chemotherapy, targeted therapy, or immunotherapy)\n\nExclusion Criteria:\n\n1. no capacity to consent;\n2. actively receiving hospice care",{"count":261,"type":20},194,[159],"This research study will help our understanding of whether additional support for Veterans with lung cancer can improve their quality of life.",[193,265,80,266,267,268],"Lung Adenocarcinoma","Lung Carcinoma","Lung Cancer, Small Cell","Lung Adenocarcinoma With Bronchiolo-alveolar Feature",[270,271],"lung","cancer","2026-03-02",{"date":274,"type":31},"2026-03-03",{"date":276,"type":31},"2026-02-27",{"date":278,"type":20},"2032-12-31",{"name":280,"class":38},"Palo Alto Veterans Institute for Research",{"id":282,"slug":283,"hasResults":12,"nctId":284,"briefTitle":285,"officialTitle":286,"acronym":4,"eligibilityCriteria":287,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":288,"targetDuration":4,"studyType":50,"phases":290,"briefSummary":291,"conditions":292,"keywords":296,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":303,"lastUpdatePostDateStruct":304,"startDateStruct":306,"completionDateStruct":308,"leadSponsor":310,"locationsCount":251},"100604110","phase-1-phase-12-dose-finding-safety-and-pk-study-in-advanced-refractory-solid-tumors-100604110","NCT07145255","Phase 1\u002F2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors","A Multicenter, Open-label Phase 1\u002F2 Dose Finding, Safety, and Pharmacokinetic Study of MBRC-201, an Antibody-drug Conjugate, in Advanced Refractory Solid Tumors","Inclusion Criteria: Patients are eligible to be included in the study only if all of the following criteria apply:\n\n1. Provide written consent on an informed consent form (ICF), approved by an Institutional Review Board (IRB)\u002FIndependent Ethics Committee (IEC), prior to any study-specific evaluation. Patients should have the ability to read and understand the ICF, ask for any clarifications from the study staff, and be able to comply with all planned study procedures.\n2. 18 years of age or older at the time of informed consent.\n3. Female patients must be at least 2 years postmenopausal (defined as 2 years without menses), surgically sterile (at least 6 months prior to dosing; must be documented) or patients of childbearing potential under the following conditions:\n\n   * Must be nonlactating and have a negative serum (preferred) or urine pregnancy test results within 72 hours prior to the first dose of MBRC-201.\n   * Must agree not to try to become pregnant during the study and for at least 6 months after the final dose of MBRC-201\n   * Must agree to practice effective contraception (must agree to use 2 forms of contraception, 1 of which must be a barrier method) and willing to continue to use effective contraception for the duration of study participation and for 6 months after the final dose of study drug.\n4. Male patients whose partners are of childbearing potential must agree to use effective contraception (must agree to use 2 forms of contraception, 1 of which must be a barrier method) (Section 10.4) for the duration of study participation and for 6 months after the final dose of study drug.\n5. Have a histologic or cytologic diagnosis of malignant solid tumor for which there are no standard-of-care treatment options known to confer a clinical benefit or for which the patient is ineligible or declines (except for Phase 1b-Cohort A).\n\n   A. For Phase 1a dose escalation: Patients must have one of the following tumor types:\n\n   i. mCRPC, breast cancer (TNBC, HR+\u002FHER2-negative or HER2-low, HR-\u002FHER2+), CRC, NSCLC, or PDAC\n\n   B. For Phase 1b: Patients must have one of the following tumor types:\n\n   i. Cohort A: Histologic or cytologic diagnosis of mCRPC (with confirmed adenocarcinoma histology) refractory to standard treatment.\n\n   Patients must have had prior exposure to at least one novel AR-targeted therapy (e.g., abiraterone acetate, enzalutamide, apalutamide, darolutamide). Prior taxane or lutetium Lu 177 vipivotide tetraxetan is acceptable but not required.\n\n   ii. Cohort B: Histologic or cytologic diagnosis of advanced metastatic NSCLC refractory to standard treatment.\n\n   iii. Cohort C: Histologic or cytologic diagnosis of advanced metastatic breast cancer (TNBC, HR+\u002FHER2-negative or HER2-low, HR-\u002FHER2+) refractory to standard treatment.\n\n   iv. Cohort D: Histologic or cytologic diagnosis of advanced metastatic CRC, PDAC refractory to standard treatment. The Sponsor may add or remove specific tumor indications based on emerging, real-time study results.\n6. Availability of a tumor tissue sample (formalin-fixed paraffin-embedded \\[FFPE\\]) must be confirmed if feasible. Patients without tumor sample may be eligible with medical monitor approval. Tumor biopsies are not required and should not be performed to assess eligibility.\n7. For Dose Escalation (Phase 1a), patients may have evaluable disease or measurable disease according to Response Evaluation Criteria in Solid Tumor (RECIST) v1.1. For both Dose Expansion (Phase 1b) and Phase 2, patients must have measurable disease according to RECIST v1.1\n8. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.\n9. Life expectancy ≥ 3 months\n10. Patient must have adequate organ and marrow function as defined below.\n\n    * Absolute neutrophil count (ANC) ≥ 1500\u002FuL\n    * Hemoglobin (Hgb) ≥ 9 g\u002FdL\n    * Platelet count ≥ 100,000\u002FuL\n    * International normalized ratio (INR) \\\u003C 1.5 (or ≤ 3.0 if on therapeutic anticoagulation)\n    * Estimated glomerular filtration rate (eGFR) ≥ 60 mL\u002Fmin by the CKD-EPI or similar equation or as measured by 24-hour urine collection\n    * Total bilirubin ≤ 1.5 × ULN \\[or ≤ 3-times ULN for patients with Gilbert's disease or documented hepatic tumor involvement\\]\n    * ALT and AST ≤ 3 × ULN \\[or ≤ 5-times ULN for patients with documented hepatic tumor involvement\\]\n\nExclusion Criteria: Patients are excluded from the study if any of the following criteria apply:\n\n1. History of another malignancy within 3 years before the first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy. Allowed exceptions are patients with:\n\n   1. Non-melanoma skin cancer considered completely cured;\n   2. Localized prostate cancer treated with curative intent with no evidence of progression;\n   3. Low-risk or very low-risk (per standard clinical guidelines) localized prostate cancer under active surveillance without immediate intent to treat;\n   4. Malignancy that is otherwise considered cured with minimal risk of recurrence.\n2. Known or suspected sensitivity to any of the ingredients of the investigational product MBRC-201.\n3. Active cerebral\u002Fmeningeal disease related to the underlying malignancy. Patients with a history of cerebral\u002Fmeningeal disease related to the underlying malignancy are allowed if prior central nervous system disease has been treated and the patient is clinically stable. (defined as not having received steroid treatment for symptoms related to cerebral\u002Fmeningeal disease for at least 2 weeks prior to the first dose of study drug and with no ongoing related AEs).\n4. Any uncontrolled viral, bacterial, or fungal infection within 2 weeks prior to the first dose of study drug, unless deemed not clinically significant by the investigator (e.g., onychomycosis). Routine antimicrobial prophylaxis is permitted.\n5. Active or symptomatic viral hepatitis, including patients with active hepatitis C infection (positive by polymerase chain reaction or on antiviral therapy for hepatitis C within the last 6 months). Patients who have been treated for hepatitis C infection or who have spontaneously recovered are permitted.\n6. Patients with HIV infection with 1 or more of the following:\n\n   * Acquired immunodeficiency syndrome (AIDs)-defining opportunistic infection within 6 months of the start of screening\n   * A change in antiretroviral therapy within 3 months of the start of screening and viral load \\> 500 copies\u002FmL\n   * Receiving antiretroviral therapy that may interfere with study drug\n   * CD4 count \\\u003C 350 at screening\n7. Thromboembolic events and\u002For bleeding disorders ≤ 14 days (e.g., venous thromboembolism \\[VTE\\] or pulmonary embolism \\[or PE\\]) prior to the first dose of study drug\n8. Documented history of a cerebral vascular event (stroke or transient ischemic attack), unstable angina, myocardial infarction, or cardiac symptoms (including congestive heart failure) consistent with New York Heart Association Class III-IV within 6 months prior to the first dose of study drug\n9. A baseline QT (time from the beginning of the Q wave to the end of the T wave) interval as corrected by Fridericia's formula (QTcF) \\> 470 msec or patients with risk factors for Torsades de pointes\n10. Uncontrolled Inflammatory Bowel Disease (IBD)\n11. A history of (non-infectious) ILD\u002Fpneumonitis requiring steroid therapy, or active ILD\u002Fpneumonitis, or clinically suspected ILD\u002Fpneumonitis that cannot be ruled out by imaging at screening\n12. Uncontrolled autoimmune disease or syndrome\n13. Active ocular surface disease at screening, including confluent superficial keratitis, cornea epithelial defect, corneal ulcer or stromal opacity or any components of the ophthalmologic history which, in the investigator's opinion, may place the patient at significant risk. Cataracts alone are not an exclusion criterion.\n14. Any anticancer therapy within 14 days prior to the first dose of study drug, including: small molecules, immunotherapy, chemotherapy, monoclonal antibody therapy, radiotherapy, or any other agents to treat cancer (anti-hormonal therapy given for advanced prostate cancer or as adjuvant therapy for early stage, HR positive breast cancer is not considered cancer therapy for the purpose of this protocol).\n15. Use of any investigational drug within 14 days prior to the first dose of study drug.\n16. For Phase 1b and Phase 2: prior treatment with an ADC with a camptothecin (CPT) payload, such as Enhertu (trastuzumab deruxtecan), Datroway (datopotamab deruxtecan), or Trodelvy (sacituzumab govitecan). Prior treatment with irinotecan and other non-ADC topoisomerase inhibitors is allowed in all phases of the study.\n17. Current use of any prohibited concomitant medication(s).\n18. Major surgery within 28 days prior to first dose of study drug.\n19. Patients who have not recovered from AEs due to prior anticancer therapy (i.e., have residual toxicities \\> Grade 1) with the exception of alopecia\n20. Any medical, psychiatric, addictive, or other kind of disorder which compromises the ability of the patient to give written informed consent and\u002For to comply with procedures.\n21. Condition or situation which, based on Investigator or Sponsor assessment, may put the patient at significant risk, may confound the study results, or may interfere significantly with patient's participation in the study.\n22. Other serious underlying medical condition that would impair the patient's ability to receive or tolerate the planned treatment and follow-up",{"count":289,"type":20},150,[190,52],"This is a multicenter, open-label FIH, Phase 1a (dose escalation), Phase 1b (dose expansion) and Phase 2 study in patients with advanced metastatic solid tumors refractory to standard treatment.",[293,162,294,55,295],"Prostate Cancer Castration-resistant Prostate Cancer","Colo-rectal Cancer","Pancreas Cancer, Duct Cell Adenocarcinoma",[297,298,299,300,301,302],"ADC","prostate cancer","breast cancer","colorectal cancer","non-small cell lung cancer","MBrace","2026-02-15",{"date":305,"type":31},"2026-02-17",{"date":307,"type":31},"2025-09-03",{"date":309,"type":20},"2029-12-30",{"name":311,"class":65},"MBrace Therapeutics",{"id":313,"slug":314,"hasResults":12,"nctId":315,"briefTitle":316,"officialTitle":317,"acronym":4,"eligibilityCriteria":318,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":319,"targetDuration":4,"studyType":50,"phases":321,"briefSummary":322,"conditions":323,"keywords":328,"overallStatus":170,"whyStopped":4,"lastUpdateSubmitDate":333,"lastUpdatePostDateStruct":334,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":340,"locationsCount":117},"100624096","phase-2-ivonescimab-alone-and-with-carboplatinpemetrexed-for-nsclc-100624096","NCT07405190","Ivonescimab Alone And With Carboplatin\u002FPemetrexed For NSCLC","A Phase II Study of Ivonescimab as Monotherapy or in Combination With Platinum\u002FPemetrexed Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Harboring Actionable Genomic Alterations (AGAs)","Inclusion Criteria:\n\n* Histologically or cytologically confirmed advanced or metastatic non-squamous NSCLC not amenable to curative resection or radiation.\n* AGA requirements as follows:\n\nIvonescimab monotherapy: Tumor harboring classical EGFR sensitizing mutation (i.e., L858R, exon 19 deletion), or ALK, ROS1, RET, or NTRK1-3 fusion, per local testing. Note: The number of patients with EGFR mutation-positive NSCLC enrolled will be capped at maximum of 10 (in order to ensure the assessment of non-EGFR disease subsets). Ivonescimab plus carboplatin\u002Fpemetrexed: Tumor harboring ALK, ROS1, RET, or NTRK1-3 fusion, per local testing.\n\n* Prior therapy requirements as follows:\n\n  a. Prior genotype-specific standard-of-care targeted therapy must have included at least one genotype-appropriate TKI(s) specified below: i. EGFR sensitizing mutation: a third-generation EGFR TKI such as osimertinib or lazertinib ii. ALK fusion: a third- or fourth-generation ALK TKI such as lorlatinib or neladalkib (NVL-655) iii. ROS1 fusion: crizotinib, entrectinib, repotrectinib, or taletrectinib iv. RET fusion: selpercatinib or pralsetinib v. NTRK1-3 fusion: entrectinib, larotrectinib, or repotrectinib Ivonescimab monotherapy: Must have received platinum\u002Fpemetrexed chemotherapy. No limitations on the number of prior lines of systemic therapy including the number of lines of chemotherapy or TKI(s). Ivonescimab plus carboplatin\u002Fpemetrexed: May not have received any prior chemotherapy. No limitations on the number of prior TKI(s).\n* At least 1 measurable lesion as assessed by investigator per the RECIST v1.1 criteria for both cohorts.\n* Participants must be willing to undergo the mandatory pre-treatment and post-progression tissue biopsies. If archival pre-treatment tissue is available from within 6 months of study enrollment, with no new intervening systemic therapy since the biopsy, a repeat pre-treatment biopsy may be omitted upon discussion with the principal investigator. On-treatment tissue biopsy (obtained within 7 days prior to Cycle 2 Day 1) will be mandatory for patients in Cohort 1 and optional for patients in Cohort 2. In select cases, if medically deemed unsafe\u002Fnot feasible, exception may be granted upon discussion with the principal investigator.\n* Clinically asymptomatic treated or untreated brain metastases are allowed if they have not required increasing doses of steroids within 2 weeks prior to study entry for CNS symptoms.\n* Age ≥18 years old.\n* ECOG performance status of 0 or 1.\n* Adequate Organ Function:\n\n  a. Hematology (no blood transfusions or growth factor therapy used within 7 days of the screening CBC): i. Absolute neutrophil count (ANC) ≥ 1.5 × 109\u002FL ii. Platelet count ≥ 100 × 109\u002FL iii. Hemoglobin ≥ 9.0 g\u002FdL b. Kidneys: i. Creatinine clearance (CrCl) ≥ 50 mL\u002Fmin using the Cockcroft-Gault formula (Cohorts 1 and 2) or estimated glomerular filtration rate (eGFR) value ≥ 60 mL\u002Fmin (for Cohort 1) or ≥30 mL\u002Fmin (for Cohort 2) using the Cockcroft-Gault formula or estimated glomerular filtration rate (eGFR) ii. Urine protein \\\u003C 2+ or 24 hour urine protein quantification \\\u003C 1.0 g c. Liver: i. Serum total bilirubin (TBIL) ≤ 1.5 × upper limit of normal (ULN); for patients with liver metastases or confirmed\u002Fsuspected Gilbert syndrome, TBIL ≤3 × ULN ii. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT)\n  * 2.5 × ULN; for patients with liver metastases, AST and ALT ≤ 5 × ULN d. Coagulation: prothrombin time (PT) or international normalized ratio (INR)\n  * 1.5 x ULN, and partial prothrombin time (PTT) or activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN (unless abnormalities are unrelated to coagulopathy). This applies only to patients who are not on therapeutic anti-coagulation. Patients receiving therapeutic anti-coagulation should be on a stable dose for at least one month prior to study enrollment.\n* Female patients of childbearing age must have negative serum pregnancy test results before first ivonescimab drug dose or per region-specific guidance documented in the informed consent and a negative urine pregnancy test on the day of first dose prior to dosing.\n* Female patient of childbearing potential having sex with an unsterilized male partner must agree to use a highly effective method of contraception from the beginning of screening until 90 days after the last dose of the ivonescimab and until 6 months after the last doses of carboplatin and pemetrexed.\n* Unsterilized male patients having sex with a female partner of childbearing potential, or a pregnant or breastfeeding partner must agree to use barrier contraception (male condom) for the duration of the treatment period until 90 days after the last dose of ivonescimab and until 90 days after the last doses of carboplatin and pemetrexed. Male patients with female partners of childbearing potential must have the female partner agree to use at least 1 form of highly effective contraception for the duration of the treatment period until 90 days after the last dose of ivonescimab and until 90 days after the last doses of carboplatin and pemetrexed.\n\nExclusion Criteria:\n\n* Participants previously treated with immune checkpoint inhibitors or other T cell immune-modulating antibodies, including anti-CTLA-4, anti-PD-1 and\u002For anti-PD-L1 agents.\n* Major surgical procedures or serious trauma within 4 weeks prior to first ivonescimab dose or plans for major surgical procedures within 4 weeks after the first ivonescimab dose (as determined by the investigator). Minor local procedures (excluding central venous catheterization and port implantation) within 3 days prior to first ivonescimab dose.\n* History of bleeding tendencies or coagulopathy and\u002For clinically significant bleeding symptoms or risk within 4 weeks prior to first ivonescimab dose, including but not limited to:\n\n  1. Hemoptysis (defined as coughing up ≥ 0.5 teaspoon of fresh blood or small blood clots). Note: transient hemoptysis associated with diagnostic bronchoscopy is allowed.\n  2. Nasal bleeding\u002Fepistaxis (bloody nasal discharge is allowed)\n  3. Current use of prophylactic or full-dose anticoagulants or anti-platelet agents for therapeutic purposes that is not stable prior to first ivonescimab dose is not allowed; stability of anti-coagulation dosing will be defined by remaining on the same dose for at least one month prior to study enrollment.\n  4. The use of full-dose anticoagulants is permitted as long as the international normalized ratio (INR) or activated partial thromboplastin time (aPTT) is within therapeutic limits according to the medical standard of the enrolling institution.\n* Poorly controlled hypertension with repeated systolic blood pressure ≥ 150 mmHg or diastolic blood pressure ≥ 100 mmHg after oral antihypertensive therapy.\n* Active autoimmune or lung disease requiring systemic therapy (eg, with disease modifying drugs, prednisone \\>10 mg daily or equivalent, immunosuppressant therapy) within 2 years prior to first ivonescimab dose; however, the following will be allowed:\n\n  1. Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is permitted.\n  2. Intermittent use of bronchodilators, inhaled corticosteroids, or local corticosteroid injections is permitted.\n* History of major diseases before first ivonescimab dose, specifically:\n\n  1. Unstable angina, myocardial infarction, congestive heart failure (New York Heart Association \\[NYHA\\] classification ≥ grade 2) or unstable vascular disease (eg, aortic aneurysm at risk of rupture, Moyamoya disease) that required hospitalization within 6 months prior to first ivonescimab dose, or other cardiac impairment that may affect the safety evaluation of the study drug (eg, poorly controlled arrhythmias, myocardial ischemia)\n  2. History of esophageal gastric varices, severe ulcers, wounds that do not heal, abdominal fistula, intra-abdominal abscesses, or acute gastrointestinal bleeding within 6 months before first ivonescimab dose\n  3. History of any grade arterial thromboembolic event, Grade 3 and above venous thromboembolic event, as specified in National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) 6.0, transient ischemic attack, cerebrovascular accident, hypertensive crisis, or hypertensive encephalopathy within 6 months prior to first ivonescimab dose\n  4. Acute exacerbation of chronic obstructive pulmonary disease within 4 weeks before first ivonescimab dose\n  5. History of perforation of the gastrointestinal tract and\u002For fistula, history of gastrointestinal obstruction (including incomplete intestinal obstruction requiring parenteral nutrition), extensive bowel resection (partial colectomy or extensive small bowel resection) within 6 months prior to first ivonescimab dose\n* Imaging during the screening period shows that the patient has:\n\n  1. Radiologically documented evidence of major blood vessel invasion (central pulmonary artery, central pulmonary veins, aorta, brachiocephalic artery, common carotid artery, subclavian artery, superior vena cava) or tumor invading organs (heart, trachea, esophagus, central bronchi \\[not including segmental bronchi\\]) or if there is a risk of esophagotracheal or esophagopleural fistula in the opinion of the investigator.\n  2. Radiographic evidence of major blood vessel encasement with narrowing of the vessel or intratumor lung cavitation or necrosis that the investigator determines will pose a significantly increased risk of bleeding.\n* Symptomatic CNS metastases, CNS metastases with hemorrhagic features, CNS metastasis ≥ 1.5 cm, CNS radiation within 7 days prior to first ivonescimab dose, potential need for CNS radiation within the first cycle, or leptomeningeal disease.\n\nNote: Patients must have stopped corticosteroids or be on physiologic corticosteroid replacement therapy (prednisone ≤ 10 mg daily or equivalent).\n\n* Live vaccine or live attenuated vaccine within 4 weeks prior to planned first ivonescimab dose, or if scheduled to receive a live vaccine or live attenuated vaccine during the study period. Inactivated vaccines are permitted.\n* Severe infection within 4 weeks prior to first ivonescimab dose, including but not limited to comorbidities requiring hospitalization, sepsis, or severe pneumonia; active infection (as determined by the investigator) requiring systemic anti-infective therapy within 2 weeks prior to first ivonescimab dose (excluding antiviral therapy for hepatitis B or C)\n* Has pre-existing peripheral neuropathy that is ≥ Grade 2 by CTCAE version 6\n* Uncontrolled pleural effusions, pericardial effusions, or ascites that is clinically symptomatic Note: Patients managed with indwelling catheters (eg, PleurX) are allowed.\n* Any evidence of current ILD or pneumonitis or a prior history of ILD or non-infectious pneumonitis requiring systemic corticosteroids\n* Active or prior history of inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis, or chronic diarrhea)\n* Known history of human immunodeficiency virus (HIV) whose viral load is not controlled.\n* Current use of systemic corticosteroids (\\>10 mg daily prednisone or equivalent)\n* Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation\n* Patients with active hepatitis B are required to have stable or declining levels of hepatitis B DNA by polymerase chain reaction (PCR) on appropriate anti-viral therapy with acceptable tolerability for one month prior to first ivonescimab dose. All patients with active hepatitis C (hepatitis C virus \\[HCV\\] antibody positive with HCV RNA levels above the lower limit of detection) are excluded.\n* Known allergy to any component of any study drug; known history of severe hypersensitivity to other monoclonal antibodies\n* History or current evidence of any condition (medical \\[including adverse events from prior anticancer therapy, disorders secondary to tumor\\], surgical or psychiatric \\[including substance abuse\\]), or laboratory abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, might lead to higher medical risk and\u002For is not in the best interest of the patient to participate, in the opinion of the treating investigator\n* Patient is breastfeeding or plans to breastfeed during the study",{"count":320,"type":20},46,[52],"The goal of this clinical trial is to assess the efficacy of ivonescimab monotherapy in patients with advanced non-small cell lung cancer harboring actionable genomic alterations who have received prior targeted therapies and chemotherapy. This clinical trial also aims to assess the efficacy of ivonescimab plus carboplatin\u002Fpemetrexed chemotherapy in patients with advanced non-small cell lung cancer harboring actionable genomic alterations other than epidermal growth factor receptor mutations who have received prior targeted therapies but no chemotherapy. The main questions it aims to answer are:\n\n* Will ivonescimab alone or together with carboplatin\u002Fpemetrexed chemotherapy shrink tumors in the clinical trial's patients?\n* Will ivonescimab alone or together with carboplatin\u002Fpemetrexed chemotherapy effectively influence if the patients' cancer grows, how long the treatment takes to start working, how long the treatment keeps working after it first starts to help, how long the treatment keeps the cancer from getting worse, and overall survival of patients?\n* How many patients receiving ivonescimab alone or together with carboplatin\u002Fpemetrexed chemotherapy will experience treatment-emergent, treatment-related, immune-related, and especially interesting side effects? Patients receiving ivonescimab alone will receive an intravenous infusion of ivonescimab every 3 weeks for up to 24 months. Patients receiving ivonescimab together with carboplatin\u002Fpemetrexed chemotherapy will receive separate intravenous infusions of ivonescimab, pemetrexed, and carboplatin every 3 weeks for 4 cycles (each cycle is 21 days). These patients will continue to receive infusions of ivonescimab and pemetrexed every 3 weeks for up to 24 total months.",[193,324,55,325,326,327],"Lung Cancer Non-Small Cell Cancer (NSCLC)","Lung Cancer - Non Small Cell","Lung Cancer Non Small Cell","Genomic Alterations",[196,329,103,330,331,332],"AGAs","non-small cell","chemotherapy","ivonescimab","2026-02-05",{"date":335,"type":31},"2026-02-12",{"date":337,"type":20},"2026-08-04",{"date":339,"type":20},"2029-03-01",{"name":341,"class":38},"Massachusetts General Hospital",{"id":343,"slug":344,"hasResults":12,"nctId":345,"briefTitle":346,"officialTitle":347,"acronym":4,"eligibilityCriteria":348,"healthyVolunteers":12,"sex":16,"minAge":349,"maxAge":4,"enrollmentInfo":350,"targetDuration":4,"studyType":50,"phases":352,"briefSummary":353,"conditions":354,"keywords":355,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":366,"lastUpdatePostDateStruct":367,"startDateStruct":369,"completionDateStruct":371,"leadSponsor":373,"locationsCount":39},"100547227","phase-1-evaluation-of-programmed-death-ligand-1-pdl1-response-to-treatment-in-extracellular-vesicles-evs-patient-derived-organoid-pdoss-and-immune-marker-positron-emission-tomography-pet-scanning-in-non-small-cell-lung-cancer-nsclc-100547227","NCT06405230","Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)","A Pilot\u002FExploratory Translational Study to Evaluate Response to Dostarlimab and Pembrolizumab in Extracellular Vesicles (EVs) or Patient-derived Organoids (PDOs) and by Zirconium-89 Labelled Programmed Death Ligand 1 Positron Emission Tomography in Participants With Recurrent Non-small Cell Lung Cancer","Inclusion Criteria:\n\n* Participants must have histologically- or cytologically documented NSCLC who present with recurrent advanced or metastatic disease after initial diagnosis of Stage 1-3 lung cancer\n* Participants must have been initially diagnosed with operable Stage 1-3 NSCLC and received curative resection ± (neo) adjuvant treatment\n* Identifiable PDL1 status prior to randomisation\n* Participants must have biopsy-confirmed recurrence of their initial NSCLC with advanced\u002Fmetastatic presentation\n* Has at least 1 measurable (target) lesion per Response Evaluation Criteria in Solid Tumours (RECIST) version (v) 1.1 by Computed tomography (CT) or magnetic resonance imaging (MRI). Measurable lesions that have been previously irradiated are not considered measurable and cannot be target lesions\n* Participants must be deemed by investigator to be appropriate to receive 1L systemic therapy (i.e., anti-PD1 ± PBCD)\n* Participants must have had tissue submitted for attempted PDO generation. (Note: patients deemed to have successfully established paired 1o PDO \\[from the tumour resection at time of diagnosis\\]are those whose PDO cultures have been passaged 2 times, with a reasonable proliferation rate. This designation can be made prior to or during trial participation. A KCL biobank pathologist will confirm the PDO's representation of clinical tumour tissue sample at the time of multiomic analysis).\n* Participants with known human immunodeficiency virus (HIV) infection are allowed with the following requirements:\n\n  1. Documented evidence of plasma HIV-1 ribonucleic acid (RNA) persistently \\\u003C50 copies per millilitre (c\u002FmL) ≤3 months prior to and at Screening. In the \\>3 to 12 months prior to Screening, plasma HIV-1 RNA consistently \\\u003C50 c\u002FmL required; if single increases ≥50 c\u002FmL occurred, they cannot have been persistent nor associated with antiretroviral resistance per investigator assessment\n  2. cluster of differentiation 4 (CD4) cell count \\>350 cells per cubic millimetre (cells\u002Fmm\\^3) over past 12 months and at Screening (and no measurement ≤350 cells\u002Fmm3 during that time period)\n  3. Must be on an uninterrupted combination antiretroviral therapy regimen for at least 3 months prior to Screening, with combination antiretroviral therapy regimen consistent with locally recommended guidelines\n  4. Participants with history of Centres for Disease Control and Prevention (CDC) Stage 3 acquired immunodeficiency syndrome (AIDS)-defining disease are allowed if AIDS-defining disease has been treated and cured or is stable for ≥3 months prior to study entry. Cutaneous Kaposi's sarcoma not requiring systemic therapy is allowed\n  5. No history of HIV-associated non-Hodgkin lymphoma ≤5 years prior to study entry\n  6. No treatment with an HIV-1 immunotherapeutic vaccine within 90 days of Screening\n* Fresh tumour biopsy (taken as part of disease recurrence evaluation) is a requirement, provided that a biopsy procedure is technically feasible and the procedure is not associated with unacceptable clinical risk. If fresh biopsy sample is not available, an archival sample may be used\n* Has an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 2\n* Has adequate organ function per the investigator\n\nExclusion Criteria:\n\n* Mixed lung carcinoma (small cell carcinoma and NSCLC), small cell carcinoma, large cell neuroendocrine carcinoma, sarcomatoid carcinoma, or any other histologies that would not benefit from anti-PD1 ± PBCD. If a potential participant has histology other than squamous cell or adenocarcinoma (e.g., mixed histology that is predominantly NSCLC, large cell without neuroendocrine features) but is deemed appropriate for treatment with anti-PD1 ± PBCD, they may be eligible pending discussion with the sponsor.\n* For participants who received adjuvant therapy that included anti-PD(L)1 Checkpoint inhibitor (CPI) following surgical resection, their last dose of anti-PD(L)1 was \\\u003C6 months from the date of first 89Zr-durvalumab-PET tracer injection\n* Participant has known central nervous system (CNS) metastases and\u002For carcinomatous meningitis that per investigator puts the participant at prohibitive risk to enrol in study\n* Participant has a known additional malignancy that progressed or required active treatment within the last 2 years. Participant with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with assessments of the study may be included only after discussion with the Medical Monitor\n* Participant is considered a poor medical risk by the investigator due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active infection requiring systemic therapy. Specific examples include, but are not limited to, active, non-infectious pneumonitis; uncontrolled chronic obstructive pulmonary disease; uncontrolled ventricular arrhythmia; recent (within 90 days) myocardial infarction; uncontrolled major seizure disorder; unstable spinal cord compression; superior vena cava syndrome; or any psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study (including obtaining informed consent)\n* Participant is pregnant or breastfeeding or expecting to conceive children within the projected duration of the study, starting with the Screening Visit through 150 days after the last dose of study treatment\n* Participant has a diagnosed immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy that per investigator puts the participant at prohibitive risk to enrol in the study\n* Participant has an active HIV infection that per investigator puts the participant at prohibitive risk to enrol in study\n* Participant has tested positive for the presence of hepatitis B surface antigen and\u002For Hepatitis B virus (HBV) core antibody or has a positive hepatitis C antibody test result at Screening or within 3 months prior to first dose of anti-cancer treatment\n* Participant has an active autoimmune disease that has required systemic treatment (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy up to 5 milligrams (mg) prednisone or equivalent for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. Use of inhaled steroids, topical steroids, local injection of steroids, and steroid eye drops are allowed\n* Participant has history of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan that per investigator and medical monitor puts the participant at prohibitive risk to enrol in study\n* Participant is currently participating and receiving study therapy or has participated in a study of an investigational agent and received investigational therapy or used an investigational device within 4 weeks prior to the first dose of study drug\n* Has cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, oesophageal\u002Fgastric varices, or persistent jaundice\n* Participant has not recovered adequately (≤ Grade 1) per investigator from AEs and\u002For complications from any major surgery prior to starting therapy\n* Participant has received a vaccine other than a vaccine against Severe acute respiratory syndrome coronavirus disease 19 (SARS-CoV-2) infection (COVID-19) within 7 days of planned start of study therapy. The use of all COVID-19 vaccines is allowed, with the exception of COVID-19 vaccines using the recombinant adenoviral vector platform within 30 days of planned start of study therapy. If a COVID-19 vaccine using this platform is to be administered within 30 days of planned start of study therapy, this must first be discussed with and approved by the sponsor's medical monitor\n* Participant has received any form of anti-cancer therapy (e.g., chemotherapy, radiation, immunotherapy) for lung cancer recurrence after initial surgery\n* Is receiving any additional anticancer post-surgery±(neo) adjuvant therapy or experimental therapy. No other experimental therapies (including but not limited to chemotherapy, radiation, hormonal treatment, antibody therapy, immunotherapy, gene therapy, vaccine therapy, or other experimental drugs) of any kind are permitted while the participant is receiving study intervention\n* NSCLC with known sensitizing EGFR mutations, Anaplastic lymphoma kinase (ALK) translocations, or c-ros oncogene 1 (ROS1) mutations from resected tissue at the time of initially surgery and\u002For tissue biopsy at the time of screening\n* Has a history of severe allergic and\u002For anaphylactic reactions to chimeric, human or humanized antibodies, fusion proteins, or known allergies to pembrolizumab, dostarlimab, durvalumab, or their excipients\n* Symptomatic herpes zoster within 3 months prior to screening\n* Evidence of active or latent tuberculosis (TB) as documented by medical history and examination, chest X-rays (posterior anterior and lateral), and TB testing: either a positive Tuberculin skin test (TST) (defined as a skin induration ≥5 millimetres \\[mm\\] at 48 to 72 hours, regardless of Bacillus Calmette-Guerin or other vaccination history) or a positive (not indeterminate) TB test such as QuantiFERON-TB Gold Plus test\n* QT interval corrected for heart rate according to Fridericia's formula (QTc) \\>450 milliseconds (msec) or QTc \\>480 msec in participants with bundle branch block","30 Years",{"count":351,"type":20},40,[190,52],"The goal of this clinical trial is to investigate the utility of biomarker tools Extracellular Vesicles (EVs), Patient-derived organoid (PDOs), and PDL1 PET imaging for predicting how participants with recurrent NSCLC respond to standard of care treatment in the advanced\u002Fmetastatic stages.",[80],[356,357,358,359,360,361,362,363,364,365],"Non-small cell lung cancer","Pembrolizumab","Dostarlimab","Platinum-based chemotherapy doublet","Programmed death ligand 1","Positron emission tomography","Extracellular Vesicles","Organoids","Artificial intelligence","Machine learning","2026-01-30",{"date":368,"type":31},"2026-02-03",{"date":370,"type":31},"2025-12-30",{"date":372,"type":20},"2029-10-10",{"name":374,"class":65},"GlaxoSmithKline",{"id":376,"slug":377,"hasResults":12,"nctId":378,"briefTitle":379,"officialTitle":380,"acronym":4,"eligibilityCriteria":381,"healthyVolunteers":12,"sex":16,"minAge":382,"maxAge":4,"enrollmentInfo":383,"targetDuration":385,"studyType":21,"phases":4,"briefSummary":386,"conditions":387,"keywords":392,"overallStatus":170,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":397,"startDateStruct":399,"completionDateStruct":401,"leadSponsor":403,"locationsCount":4},"100621573","association-of-different-tidal-volumes-and-postoperative-pulmonary-complications-100621573","NCT07372378","Association of Different Tidal Volumes and Postoperative Pulmonary Complications","Association of Various Introperative Tidal Volumes and Postoperative Pulmonary Complications After Video-assisted Thoracic Surgery","Inclusion Criteria:\n\n* Age \\> 50 years.\n* ASA physical status I-II.\n* The cardiopulmonary and other vital organ functions are basically normal, and the patient is able to tolerate surgery.\n* Ariscat score \\> 26.\n* Informed consent has been obtained.\n\nExclusion Criteria:\n\n* Patients who refuse to participate in the clinical trial, or have cognitive impairment or impaired ability to understand and express themselves.\n* ASA physical status ≥ III.\n* Patients with congestive heart failure, severe aortic stenosis, or extensive pleural adhesions.\n* Patients with severe psychiatric disorders or allergy to anesthesia-related medications.\n* Patients with severe organ dysfunction such as the liver or kidney dysfunction.","51 Years",{"count":384,"type":20},650,"7 Days","The incidence of lung cancer in China is increasing year by year. Currently, the treatment primarily based on video-assisted thoracoscopic surgery (VATS) is still considered the optimal approach for early-stage non-small cell lung cancer. The widespread application of traditional one-lung ventilation (OLV) technology not only achieves effective lung isolation, but also facilitates exposure of the surgical field during thoracoscopic surgery, making it more convenient for surgeons to operate. However, the occurrence of hypoxemia during one-lung ventilation may pose a risk to patient safety.\n\nOne-lung ventilation can lead to increased intrapulmonary shunt, ventilation\u002Fperfusion (V\u002FQ) mismatch, and ischemic-hypoxic lung injury. Hypoxemia is the major problem during one-lung ventilation. Postoperative pulmonary complications (PPCs) are among the major complications following thoracic and general anesthesia surgeries, including atelectasis, pneumonia, and respiratory failure, which significantly prolong hospital stay and increase mortality.\n\nLow tidal volume lung-protective ventilation strategies have been widely implemented. Additionally, permissive hypercapnia, reducing peak airway pressure to minimize barotrauma, and decreasing FiO₂ all help reduce pulmonary complications.Recently, researchers have focused on optimizing ventilation strategies during OLV, such as using PEEP or low VT ventilation alone or in combination, or exploring different combinations of tidal volume and respiratory frequency under consistent minute ventilation (VE), aiming to balance lung protection and oxygenation, reduce complications, and improve patient outcomes.\n\nHowever, to date, there is still no gold standard tidal volume ventilation strategy for reducing pulmonary complications in patients undergoing lung resection.",[388,389,390,391,55],"Pulmonary Complications","Hypoxemia During Surgery","Thoracic Surgery, Video Assisted","One Lung Ventillation (OLV)",[393,394,395,396],"pulmonary complications","hypoxemia","video-assisted thoracic surgery","one lung ventilation",{"date":398,"type":31},"2026-01-28",{"date":400,"type":20},"2026-01-20",{"date":402,"type":20},"2029-02-01",{"name":404,"class":38},"First Affiliated Hospital of Zhejiang University",{"id":406,"slug":407,"hasResults":12,"nctId":408,"briefTitle":409,"officialTitle":410,"acronym":4,"eligibilityCriteria":411,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":412,"targetDuration":4,"studyType":50,"phases":414,"briefSummary":415,"conditions":416,"keywords":4,"overallStatus":170,"whyStopped":4,"lastUpdateSubmitDate":430,"lastUpdatePostDateStruct":431,"startDateStruct":433,"completionDateStruct":435,"leadSponsor":437,"locationsCount":39},"100619216","phase-1-sl-28-for-advanced-solid-tumours-100619216","NCT07341737","SL-28 for Advanced Solid Tumours","A Phase 1\u002F2, Multicentre, Open-Label, Dose Escalation and Expansion Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of SL-28 in Patients With Advanced Solid Tumours","Inclusion Criteria:\n\n* Ability to provide written informed consent prior to any study-related procedures and to understand the nature, purpose, and potential risks of the study\n* Adult males and females ≥18 years of age at screening\n* Life expectancy of at least 3 months\n* Histologically or cytologically confirmed unresectable advanced solid tumor (recurrent, metastatic, or locally advanced)\n* Disease refractory to, intolerant of, or refusal of standard therapies, including immunotherapy and molecular\u002Fbiomarker-directed treatments, as determined by the Principal Investigator (PI) or delegate\n* Eligible tumor types include:\n* Head and neck squamous cell carcinoma\n* Thoracic malignancies (small-cell lung cancer, non-small cell lung cancer, esophageal cancer)\n* Gastrointestinal malignancies (gastric, liver, colorectal, pancreatic adenocarcinoma)\n* Genitourinary malignancies (bladder, renal cell, prostate cancer)\n* Gynecologic malignancies (ovarian, endometrial cancer)\n* Breast cancer and melanoma\n* Evaluable disease per RECIST v1.1\n* ECOG performance status 0-1 (or up to 2 at PI discretion)\n* Adequate organ function, defined as:\n* Total bilirubin ≤1.5 × ULN (≤2.0 × ULN for liver metastases or Gilbert's syndrome)\n* AST, ALT, alkaline phosphatase ≤2.5 × ULN (≤5 × ULN if liver metastases, at PI discretion)\n* Creatinine clearance ≥50 mL\u002Fmin (Cockcroft-Gault) or eGFR ≥50 mL\u002Fmin (CKD-EPI)\n* Absolute neutrophil count ≥1,000\u002Fmm³\n* Platelet count ≥100,000\u002Fmm³\n* Hemoglobin ≥90 g\u002FL without transfusion within 2 weeks\n* Prothrombin time and aPTT ≤1.5 × ULN (or stable INR if on anticoagulation)\n\nFemale patients:\n\n-Non-childbearing potential (surgically sterile or postmenopausal), or of childbearing potential with negative pregnancy tests and agreement to effective contraception through 90 days post-dose\n\nMale patients:\n\n* Agreement not to donate sperm for 90 days post-dose\n* Agreement to use adequate contraception as applicable\n* Suitable venous access for blood sampling\n* Willingness and ability to comply with study procedures and protocol requirements\n\nExclusion Criteria:\n\n* Ongoing toxicities ≥ Grade 2 per NCI CTCAE v5.0 (except alopecia, fatigue, sensory neuropathy, or adequately treated endocrine deficiencies)\n* NYHA Class III or IV heart disease, myocardial infarction within 6 months, unstable arrhythmia, or ischemia on ECG\n* QTcF \\>470 ms (females) or \\>450 ms (males)\n* Active, uncontrolled bacterial, viral, or fungal infection requiring systemic therapy\n* Requirement for systemic corticosteroids or other immunosuppressive therapy that cannot be discontinued ≥14 days prior to dosing\n* Prior therapies within restricted timeframes:\n* Immune checkpoint inhibitors or biologics within 28 days\n* Antineoplastic therapies, surgery, radiotherapy, or radiopharmaceuticals within 21 days\n* Unapproved investigational drugs within 5 half-lives\n* Nitrosoureas or mitomycin C within 6 weeks\n* Concurrent malignancy within 5 years, except specified low-risk cancers\n* Pregnancy or breastfeeding\n* Known HIV, hepatitis B (HBsAg positive), or hepatitis C infection\n* Inability or unwillingness to comply with protocol procedures\n* History of anaphylaxis or significant allergy interfering with participation\n* Clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, neurologic, psychiatric, or immunologic disease within 6 months\n* Conditions affecting drug absorption, distribution, metabolism, or excretion\n* Receipt of live vaccines within 28 days prior to screening\n* Participation in another investigational study within 30 days prior to screening",{"count":413,"type":20},60,[190,52],"Second Life Therapeutics is developing SL-28, an allogeneic, non-genetically modified cell-based therapy for the treatment of advanced solid tumours. The company has recently demonstrated a novel, non-genetic approach to modulate immune cell activity through targeted manipulation of the Universal Receptive System. The purpose of this open label, multi-center clinical trial is to evaluate the anti-tumor activity, safety, and pharmacokinetics, single-agent SL-28 in patients with a diverse array of solid tumors. The study includes an initial Phase 1 dose escalation to determine recommended dose(s) for expansion of SL-28 as a monotherapy and Phase 2 expansion cohorts. The study will enroll patients with advanced solid tumours, including those who failed previous lines of chemo- and immunotherapies.",[417,418,419,265,193,55,420,421,422,423,424,425,426,427,162,428,429,163],"Head & Neck Cancer","Pancreas Carcinoma","Pancreas Cancer, Metastatic","Esophageal Cancer","Stomach (Gastric) Cancer","Liver Cancer","Intestinal Cancer","Bladder Cancer","Renal Cancer","Prostate Cancer","Melanoma (Skin Cancer)","Ovarian Cancer","Endometrial Cancer","2026-01-13",{"date":432,"type":31},"2026-01-15",{"date":434,"type":20},"2026-02-01",{"date":436,"type":20},"2027-03-01",{"name":438,"class":65},"Second Life Therapeutics",{"id":440,"slug":441,"hasResults":12,"nctId":442,"briefTitle":443,"officialTitle":444,"acronym":445,"eligibilityCriteria":446,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":447,"targetDuration":4,"studyType":50,"phases":449,"briefSummary":450,"conditions":451,"keywords":455,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":457,"lastUpdatePostDateStruct":458,"startDateStruct":460,"completionDateStruct":462,"leadSponsor":464,"locationsCount":466},"100533631","phase-1-a-study-assessing-kb707-for-the-treatment-of-advanced-solid-tumor-malignancies-affecting-the-lungs-100533631","NCT06228326","A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs","KB707-02: A Phase 1\u002F2 Study of Inhaled KB707 in Patients With Advanced Solid Tumor Malignancies Affecting the Lungs","KYANITE-1","Key Inclusion Criteria:\n\n* Age 18 years or older at the time of informed consent\n* Life expectancy \\>12 weeks\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Have at least one measurable lung lesion per RECIST v1.1 at Screening\n* Cohorts 1 through 4 only: Histologically confirmed diagnosis of advanced solid tumor malignancy affecting the lungs and the individual has progressed on standard of care therapy, cannot tolerate standard of care therapy, refused standard of care therapy, or has no standard of care therapy.\n* Cohorts 5, 6, and 7 only: (1) Histologically or cytologically confirmed diagnosis of stage 3 or 4 NSCLC, as per American Joint Committee on Cancer (AJCC) staging system (8th edition) and (2) Subject must meet the following criteria of prior lines of therapy:\n\n  1. Subject has previously received no more than one line of prior immune checkpoint inhibitor (ICI) with or without platinum-based chemotherapy, or no more than two prior lines of therapy when given the ICI and platinum-based chemotherapy sequentially as two separate lines.\n  2. Subjects with an actionable mutation (e.g., EGFR, KRAS, ALK, or ROS1 genomic alteration), are permitted to have received one additional line of approved targeted therapy.\n\nKey Exclusion Criteria:\n\n* Not fully recovered from prior surgery or radiotherapy, including all radiation-related toxicities\n* The subject is pregnant, nursing, or plans to become pregnant during study treatment and through three months after the last dose of KB707\n* Have known history of positive human immunodeficiency virus (HIV 1\u002F2)\n* Cohorts 5, 6, and 7 only:\n\n  1. Subject has a known additional malignancy that is progressing or requires active treatment\n  2. Subject has active brain metastases or leptomeningeal metastases\n  3. Prior anti-PD-1\u002FPD-L1 therapy was intolerable and required discontinuation of treatment\n  4. Subject has active, known, or suspected autoimmune disease requiring systemic treatment\n  5. Subject has known acute or chronic hepatitis\n  6. Subject has active pneumonitis or history of ICI-induced pneumonitis that required steroids",{"count":448,"type":20},250,[190,52],"The Sponsor is developing KB707, a replication-defective, non-integrating herpes simplex virus type 1 (HSV-1)-derived vector designed to stimulate an anti-tumor immune response through the production of cytokines within the local tumor microenvironment in the lungs. KB707 is administered via nebulization, delivering the therapy directly through the airways to the lungs of subjects with advanced solid tumor malignancies.\n\nThis is a Phase 1\u002F2, open-label, multicenter, dose escalation and expansion study designed to evaluate the safety, tolerability, preliminary efficacy, and immunologic effect of KB707.\n\nMonotherapy KB707 dose escalation and expansion cohorts enrolled adults with advanced solid tumor malignancies affecting the lungs who had progressed on standard of care therapy, cannot tolerate standard of care therapy, or refused standard of care therapy. The dose escalation phase (Cohorts 1 and 2) evaluated KB707 monotherapy using a standard 3+3 design, followed by a dose expansion phase (Cohort 4) to further evaluate the selected dose. Subjects received inhaled KB707 weekly for three weeks, then every three weeks. The dose escalation portion of the study is now complete, and the selected dose is being evaluated in the expansion phase.\n\nCombination regimens with a selected (fixed) dose of KB707 are being evaluated in subjects with advanced or metastatic non-small cell lung cancer (NSCLC). Subjects in Cohorts 5 and 6 are receiving inhaled KB707 once every 2 weeks (q2w), delivered in combination with Keytruda once every 6 weeks. Subjects in Cohort 7 are receiving inhaled KB707 in combination with docetaxel once every 3 weeks.\n\nAll subjects will be treated until tumor progression, death, unacceptable toxicity, symptomatic deterioration, achievement of maximal response, subject choice, Investigator decision to discontinue treatment, or the Sponsor determines to terminate the study.",[24,452,453,454,193],"Lung Cancer Metastatic","Solid Tumor, Adult","Advanced Cancer",[271,456,103],"Krystal Biotech","2025-10-22",{"date":459,"type":31},"2025-10-24",{"date":461,"type":31},"2024-04-17",{"date":463,"type":20},"2028-07",{"name":465,"class":65},"Krystal Biotech, Inc.",14,{"id":468,"slug":469,"hasResults":12,"nctId":470,"briefTitle":471,"officialTitle":471,"acronym":472,"eligibilityCriteria":473,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":474,"targetDuration":4,"studyType":50,"phases":476,"briefSummary":477,"conditions":478,"keywords":4,"overallStatus":170,"whyStopped":4,"lastUpdateSubmitDate":480,"lastUpdatePostDateStruct":481,"startDateStruct":483,"completionDateStruct":485,"leadSponsor":487,"locationsCount":39},"100597627","analysis-of-circulating-tumor-markers-in-blood---alcina-5-100597627","NCT07060950","Analysis of Circulating Tumor Markers in Blood - ALCINA 5","ALCINA 5","Inclusion Criteria:\n\n1. Patient presenting an invasive tumoral pathology (proved or suspected), whatever is the location or the stage,\n2. 18 years old or higher ?\n3. Patient who has provided informed, written, and explicit consent,\n4. Patient affiliated with a French Social Protection System.\n\n   In the case of a tumor biopsy:\n5. Tumor considered as accessible by biopsy,\n6. Normal hemostasis assessment (PT, APTT, platelets),\n7. No anticoagulant or antiaggregant treatment for the biopsy.\n\nExclusion Criteria:\n\n1. Pregnant woman and\u002For breast-feeding,\n2. Patient whose regular follow-up is impossible for psychological, family, social or geographical reasons,\n3. Private persons of freedom or under guardianship,\n4. Patient with a history of other invasive cancers within the 5 years preceding inclusion.",{"count":475,"type":20},620,[159],"The circulating tumoral biomarkers in the blood are the object of numerous researches for several decades. The potential clinical interests of these circulating biomarkers are diagnostic, prognostic, predictive of the efficiency of targeted therapies (according to the mutational profile of the cancer), and could allow the study of the mechanisms of resistance under process. In the multiplicity of these blood potential biomarkers joins a permanent evolution of the technological means used to detect them\u002Fto quantify, as well as to estimate their clinical utility.",[479,80],"Cancer","2025-09-18",{"date":482,"type":31},"2025-09-19",{"date":484,"type":20},"2025-10",{"date":486,"type":20},"2035-07",{"name":488,"class":38},"Institut du Cancer de Montpellier - Val d'Aurelle",{"id":490,"slug":491,"hasResults":12,"nctId":492,"briefTitle":493,"officialTitle":494,"acronym":495,"eligibilityCriteria":496,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":497,"enrollmentInfo":498,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":500,"conditions":501,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":503,"startDateStruct":505,"completionDateStruct":507,"leadSponsor":509,"locationsCount":39},"100605706","efficacy-of-neoadjuvant-immunotherapy-in-patients-with-lung-cancer-100605706","NCT07166003","Efficacy of Neoadjuvant Immunotherapy in Patients With Lung Cancer","Effects of Neoadjuvant Immunotherapy on Patients With Lung Cancer: a Prospective, Observational Study","NeoIP-Lung","Inclusion Criteria:\n\n1. Aged between 18 and 79 years;\n2. Received at least two cycles of neoadjuvant immunotherapy;\n3. ECOG performance status score of 0;\n4. Complete clinical information including imaging data available.\n\nExclusion Criteria:\n\n1. Diagnosed with or suspected active autoimmune diseases;\n2. Presence of EGFR\u002FALK sensitive mutations;\n3. Pregnant or breastfeeding women;\n4. Previous anti-tumor therapies including chemotherapy or radiotherapy;\n5. History of organ transplantation or hematopoietic stem cell transplantation;\n6. Interstitial pneumonia, pulmonary fibrosis, or severe emphysema;\n7. Uncontrolled diabetes mellitus;\n8. Uncontrolled hypertension.","79 Years",{"count":499,"type":20},500,"The goal of this observational study is to learn about the long-term effects of neoadjuvant immunotherapy in patients with lung cancer. The main questions it aims to answer are:\n\n* Does pneumonectomy bring more benefits for pateints than lobectomy?\n* Does surgery bring more benefits for patients than non-surgery modalities (such as radiotherapy) after neoadjuvnat immunotherapy? Participants will receive neoadjuvant treatment and the study will analyze the data.",[80,502],"Immunotherapy",{"date":504,"type":31},"2025-09-10",{"date":506,"type":31},"2025-04-20",{"date":508,"type":20},"2030-04-14",{"name":510,"class":38},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",{"id":512,"slug":513,"hasResults":12,"nctId":514,"briefTitle":515,"officialTitle":516,"acronym":4,"eligibilityCriteria":517,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":518,"targetDuration":4,"studyType":50,"phases":520,"briefSummary":521,"conditions":522,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":523,"lastUpdatePostDateStruct":524,"startDateStruct":526,"completionDateStruct":528,"leadSponsor":530,"locationsCount":39},"100566735","phase-2-perioperative-tislelizumab-for-resectable-ii-iiibn2-kras-mutated-nonsquamous-non-small-cell-lung-cancer-100566735","NCT06659042","Perioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer","A Prospective, Single-arm Phase II Study of the Efficacy and Safety of Tislelizumab in Combination With Chemotherapy Perioperative Treatment for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer","Inclusion Criteria:\n\n1. Able to provide written informed consent (ICF) and able to understand and comply with the study requirements and assessment schedule.\n2. Male or female aged ≥18 years at the time of signing the ICF.\n3. Histologically or cytologically confirmed stage II-IIIB (N2) non-squamous non-small cell lung cancer (NSCLC) (AJCC 8th edition).\n4. With Known KRAS gene mutation.\n5. Evaluated by medical and surgical discussion to be eligible for R0 resection with curative intent prior to study enrollment.\n6. At least one measurable lesion as defined by RECIST v1.1.\n7. Eligible to receive platinum-based doublet chemotherapy.\n8. ECOG performance status score ≤ 1.\n9. Adequate organ function during the screening period\n10. Good cardiopulmonary function, meeting the requirements for surgical resection with curative intent.\n11. Patients of childbearing potential must be willing to use effective contraception during the study and for 120 days after the last dose of tislelizumab.\n\nExclusion Criteria:\n\nPatients meeting any of the following criteria are not eligible for enrollment:\n\n1. Previously received any treatment for the current lung cancer, including radiotherapy and all systemic anti-tumor treatments, including chemotherapy, immunotherapy, targeted therapy, or anti-angiogenic therapy.\n2. Presence of locally advanced, unresectable disease, regardless of disease stage or presence of metastases.\n3. Received other approved systemic immunomodulatory agents (including but not limited to interferon, interleukin-2, tumor necrosis factor, thymosin α1, and thymalfasin) within 4 weeks prior to the first dose.\n4. Used any herbal medicine to control cancer within 14 days prior to the first dose of the study drug.\n5. Received live or attenuated live vaccines within 4 weeks prior to enrollment or expected to require live or attenuated live vaccines during the study or within 5 months after the last dose of tislelizumab.\n6. Any condition requiring systemic corticosteroid therapy (prednisone or equivalent \\>10 mg\u002Fday) or other immunosuppressive therapy within 14 days prior to the first dose of the study drug, which the investigator believes may affect the study treatment.\n7. Active autoimmune disease requiring systemic treatment, which the investigator believes may affect the study treatment.\n8. Interstitial lung disease, non-infectious pneumonitis, or uncontrolled other diseases, including diabetes, pulmonary fibrosis, acute lung disease, etc., which the investigator believes may affect the study treatment.\n9. History of major diseases or clinical manifestations that may affect organ system function, which the investigator believes may affect the study treatment.\n10. Severe chronic or active infections requiring systemic antibacterial, antifungal, or antiviral treatment within 14 days prior to the first dose of the study drug (including tuberculosis infection, etc.).\n11. Known history of human immunodeficiency virus (HIV) infection.\n12. Previously undergone allogeneic stem cell transplantation or organ transplantation.",{"count":519,"type":20},32,[52],"The primary objective of the perioperative study is to evaluate pathological complete response in resectable II-IIIB(N2) KRAS-mutated nonsquamous non-small cell lung cancer participants receiving tislelizumab plus platinum-based doublet chemotherapy.",[80],"2025-05-14",{"date":525,"type":31},"2025-05-18",{"date":527,"type":31},"2024-11-20",{"date":529,"type":20},"2027-11-20",{"name":531,"class":38},"Shanghai Chest Hospital",{"id":533,"slug":534,"hasResults":12,"nctId":535,"briefTitle":536,"officialTitle":537,"acronym":538,"eligibilityCriteria":539,"healthyVolunteers":213,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":540,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":542,"conditions":543,"keywords":544,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":553,"lastUpdatePostDateStruct":554,"startDateStruct":556,"completionDateStruct":558,"leadSponsor":560,"locationsCount":39},"100590122","novel-epigenetic-mapping-in-cell-free-dna-for-the-detection-of-lung-cancer-100590122","NCT06963307","Novel Epigenetic Mapping in Cell-Free DNA for the Detection of Lung Cancer","LUMEN-Dx: Novel Epigenetic Mapping in Cell-Free DNA for the Detection of Lung Cancer","LumenDx","Inclusion Criteria:\n\n* Men and women over 18 years old.\n* Patients diagnosed with lung cancer before systemic therapy.\n* Patients with inconclusive LDCT findings.\n* Healthy volunteers.\n* Patients with chronic lung diseases (COPD, pulmonary emphysema, acute pneumonia).\n\nExclusion Criteria:\n\n* Subjects who did not sign a consent form.\n* Patients with cancer other than lung cancer.\n* Patients with HIV or hepatitis.\n* Patients with active autoimmune diseases (except lung-localized diseases).\n* Pregnant women or individuals unable to give informed consent.",{"count":541,"type":20},300,"This trial is a multicenter, open-label, non-interventional controlled study to identify and characterize epigenetic signatures of lung cancer. The goal of this study is to develop a simple blood test that can detect lung cancer with high sensitivity, and assist in the early diagnosis and management of lung cancer.\n\nIn particular, the ability to assist existing methods in cancer diagnostics, predict response to treatment, and assess the success of treatment during and after treatment will be examined. In addition, the ability to assess minimal residual disease (MRD) will be evaluated, by taking blood after surgery to remove a tumor or after treatment, and testing whether there is any residual DNA from the tumor using the markers that are found.\n\nThe collection of patients and data will be conducted over a period of about a year and a half, with the aim of reaching approximately 300 participants, including patients with lung cancer before and after treatment\u002Fsurgery and control groups.",[80],[103,545,546,547,548,549,550,551,552],"liquid biopsy","cancer diagnostics","follow-up","minimal residual disease","cell-free DNA","epigenetics","DNA methylation","response to therapy","2025-04-30",{"date":555,"type":31},"2025-05-09",{"date":557,"type":20},"2025-05",{"date":559,"type":20},"2026-11",{"name":561,"class":65},"JaxBio Ltd",{"id":563,"slug":4,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":564,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":565,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":566,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":567,"lastUpdatePostDateStruct":568,"startDateStruct":570,"completionDateStruct":572,"leadSponsor":573,"locationsCount":39},"100487537","Inclusion Criteria:\n\n* Cohort A, B and C :\n\n  * Written Informed consent\n  * Agreement to be followed up (including on-study assessments and sample collection) every 3 months in the first 2 years and then 6 monthly.\n  * Agreement to be followed up at a TRACERx EVO site\n\nCohort A:\n\n* Participants ≥18 years of age, with early stage I-IIIB NSCLC disease who are eligible for primary surgery\n* Histopathologically confirmed NSCLC, or a strong suspicion of cancer on lung imaging necessitating surgery (e.g., diagnosis determined from frozen section in theatre)\n* Primary surgery in keeping with NICE guidelines in (lobectomy, either open or thoracoscopic), lung parenchymal-sparing operations (segmentectomy or wedge resection) if a complete resection can be achieved, extensive surgery (bronchoangioplastic surgery, bilobectomy, pneumonectomy) if necessary to obtain clear margins, hilar and mediastinal lymph node sampling or en bloc resection)\n* For participants proceeding with upfront primary surgery (i.e. no neoadjuvant therapy), a minimum tumour diameter at least 15mm to allow for sampling of at least two tumour regions\n* Participants undergoing neoadjuvant treatment must have at least 1 region of fresh frozen or FFPE surgical or diagnostic biopsy tissue.\n* Considered sufficiently fit for upfront standard of care primary surgery or neoadjuvant therapy if indicated\n* Performance status 0 to 2\n\nCohort B:\n\n* Participants ≥18 years of age, with late-stage unresectable stage IIIB and above NSCLC disease (TNM 8th edition) or presenting with stage IV de novo metastatic disease.\n* Sufficient tissue (at least 1 region\u002Fbiopsy), either FFPE or fresh frozen\n* Deemed to be fit for anti-cancer treatment\n* Performance status 0 to 2 Participants who were initially consented into Cohort A with a post-surgical staging of stage IIIB\u002FC or IV could be included in Cohort B.\n\nCohort C:\n\n* Participants ≥18 years of age, with any stage SCLC or pleural mesothelioma.\n* Sufficient tissue (at least 1 region\u002Fbiopsy), either FFPE or fresh frozen\n* Deemed to be fit for anti-cancer treatment\n* Performance status 0 to 2\n\nExclusion Criteria:\n\n* Cohort A, B and C:\n\n  * Other active malignancy\n  * Any other\\* malignancy diagnosed or relapsed at any time, which is currently being treated (including by hormonal therapy).\n  * Any other\\* current malignancy or malignancy diagnosed or relapsed within the past 3 years\\*\\*.\n\n    * \\*Exceptions are: non-melanomatous skin cancer, stage 0 melanoma in situ, and in situ cervical cancer\n    * \\*\\*An exception will be made for malignancies diagnosed or relapsed more than 2, but less than 3, years ago only if a pre-operative biopsy of the lung lesion has confirmed a diagnosis of NSCLC.\n  * Psychological condition that would preclude informed consent\n  * Diagnosis other than NSCLC, SCLC or pleural mesothelioma confirmed following surgery or biopsy\n  * Confirmed diagnosis of known high-risk infections (e.g., Human Immunodeficiency Virus) (HIV), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) or syphilis infection, tuberculosis and Creutzfeldt-Jacob disease) unless participant case is of a particular scientific interest and agreed in advance with research staff, local mortuary staff and pathologist.\n  * Contra-indicated co-morbid conditions\n\nCohort A:\n\n* Positive margins, incomplete resection or insufficient nodal sampling\n* Insufficient tissue, i.e., for participants having upfront surgery and not having neoadjuvant therapy, a minimum of two tumour regions unlikely to be obtained for the study based on pre-operative imaging. For participants having neoadjuvant therapy i.e., at least one tissue biopsy to be obtained (Fresh Frozen or FFPE).\n* Participant found to have pre-invasive lesions rather than invasive cancer following surgery, such as adenocarcinoma in situ or minimally invasive lesions will be withdrawn. However, the surgical tissue and baseline blood already collected will be sent to the central laboratory. These participants will not be followed-up in the study or required to provide any further blood samples. If these participants subsequently develop invasive cancer, the date of diagnosis and the tumour histology will be reported on the electronic data capture system.\n\nCohort B\u002FC:\n\n• Insufficient tissue, i.e., at least one tissue biopsy to be obtained (Fresh Frozen or FFPE)",{"count":19,"type":20},[24,25,26],"2025-03-27",{"date":569,"type":31},"2025-04-02",{"date":571,"type":31},"2023-12-04",{"date":35,"type":20},{"name":37,"class":38},{"id":575,"slug":576,"hasResults":12,"nctId":577,"briefTitle":578,"officialTitle":579,"acronym":4,"eligibilityCriteria":580,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":581,"targetDuration":77,"studyType":21,"phases":4,"briefSummary":583,"conditions":584,"keywords":586,"overallStatus":170,"whyStopped":4,"lastUpdateSubmitDate":591,"lastUpdatePostDateStruct":592,"startDateStruct":594,"completionDateStruct":596,"leadSponsor":598,"locationsCount":4},"100575647","sers-based-serum-molecular-spectral-screening-for-lung-cancer-type-100575647","NCT06775002","SERS-Based Serum Molecular Spectral Screening for Lung Cancer Type","SERS-Based Serum Molecular Spectral Screening for Non-Small Cell Lung Cancer vs. Small Cell Lung Cancer: A Multicenter, Open-Label, Double-Blind, Independent Data Analysis Clinical Trial","Inclusion Criteria:\n\n1. Participants with Lung cancer meeting the criteria of TNM (Ninth Edition);\n2. Participants are willing to participate in this study and follow the research plan;\n3. Participants or legally authorized representatives can give written informed consent approved by the Ethics Review Committee that manages the website;.\n\nExclusion Criteria:\n\n1. Participants with concomitant other malignant tumors;\n2. Participants with missing baseline clinical data;\n3. Participants with severe underlying pulmonary diseases (such as bronchiectasis, bronchial asthma, or COPD), or those with a history of occupational or environmental exposure to dust, mines, or asbestos;\n4. Participants who are uncooperative or refuse to participate in the clinical trial later on.",{"count":582,"type":20},223,"Lung cancer can be divided into two major categories: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), with NSCLC accounting for about 85% and SCLC about 15%. The prognoses of different types of lung cancer vary significantly. Early identification of different pathological types of lung cancer is crucial to the patient's prognosis.\n\nRaman Spectrum (RS), as a non-invasive and highly specific molecular detection technique, can obtain information at the molecular level, thereby sensitively detecting changes in biomolecules related to tumor metabolism such as proteins, nucleic acids, lipids, and sugars. Surface-enhanced Raman spectroscopy (SERS), developed based on this technology, is one of the feasible methods for high-sensitivity biomolecular analysis.\n\nIn preliminary study, the investigators collected serum Raman spectral data from a cohort of 233 patients with malignant lung tumors and built a Raman intelligent diagnostic system for SCLC and NSCLC based on a machine learning model, achieving an accuracy rate of 80%. To obtain the highest level of clinical evidence and truly achieve clinical translation, this prospective, multicenter clinical study aims to validate the use of this intelligent diagnostic system for the early diagnosis of SCLC.",[80,585],"Lung Cancer Small Cell Lung Cancer (SCLC)",[587,588,196,589,590],"SERS","Raman","SCLC","diagnostic model","2025-03-26",{"date":593,"type":31},"2025-03-31",{"date":595,"type":20},"2026-04-05",{"date":597,"type":20},"2026-11-20",{"name":599,"class":38},"Fuzhou General Hospital",{"id":601,"slug":602,"hasResults":12,"nctId":603,"briefTitle":604,"officialTitle":605,"acronym":606,"eligibilityCriteria":607,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":608,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":609,"conditions":610,"keywords":611,"overallStatus":170,"whyStopped":4,"lastUpdateSubmitDate":615,"lastUpdatePostDateStruct":616,"startDateStruct":618,"completionDateStruct":620,"leadSponsor":622,"locationsCount":4},"100571844","comprehensive-demographics-and-clinical-profile-of-nsclc-patients-100571844","NCT06725537","Comprehensive Demographics and Clinical Profile of NSCLC Patients","Comprehensive Demographics and Clinical Profile of NSCLC Patients: Analyzing Treatment Patterns With PD-L1 Stratification","CA209-1529","Inclusion Criteria:\n\n* Over 18 years old;\n* Histological diagnosis of advanced non-small cell cancer;\n* Clinical and demographic data available in medical records;\n\nExclusion Criteria:\n\n* Patients with localized disease that can be treated locally;\n* Non-epithelial histology;\n* small cell carcinoma\n* neuroendocrine tumor",{"count":499,"type":20},"Advances in the treatment of non-small cell lung cancer in the last decade have been significant. Currently, there are several first-line therapeutic options. The molecular biology of the disease, biomarkers and the patient's clinical characteristics can assist in decision making. The study in question aims to retrospectively evaluate the patterns of choice in the first line treatment of metastatic non-small cell lung cancer without driver mutations, from 2019 to 2022 in 7 centers in Brazil.",[326],[612,270,613,614],"neoplasia","metastasis","first line treatment","2025-01-13",{"date":617,"type":31},"2025-01-15",{"date":619,"type":20},"2025-01-20",{"date":621,"type":20},"2025-08-01",{"name":623,"class":38},"D'Or Institute for Research and Education",{"id":625,"slug":626,"hasResults":12,"nctId":627,"briefTitle":628,"officialTitle":629,"acronym":4,"eligibilityCriteria":630,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":47,"enrollmentInfo":631,"targetDuration":4,"studyType":50,"phases":633,"briefSummary":634,"conditions":635,"keywords":636,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":640,"lastUpdatePostDateStruct":641,"startDateStruct":643,"completionDateStruct":645,"leadSponsor":646,"locationsCount":39},"100575208","phase-2-a-phase-ii-study-of-ak112-pd1vegf-bispecific-in-combination-with-chemotherapy-in-patients-with-nsclc-100575208","NCT06769295","A Phase II Study of AK112 (PD1\u002FVEGF Bispecific) in Combination with Chemotherapy in Patients with NSCLC","A Phase II Study of AK112 (PD-1\u002FVEGF Bispecific) in Combination with Chemotherapy for Patients with Advanced Non-squamas Non-mall Cell Lung Cancer and Malignant Pleural Effusion","Inclusion Criteria:\n\n* 18 to 75 years old (at the time of inform consent obtained)；\n* Have histologically- or cytologically-confirmed diagnosis of Stage IV non-squamas NSCLC；\n* The presence of malignant pleural effusion (positive pleural effusion cytology or multiple pleural nodules or thickening with pleural effusion on CT imaging)；\n* Driver gene mutation negative；\n* Have a life expectancy of at least 3 months；\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2；\n* Has adequate organ function；\n* Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 assessed by investigator；\n* Be able to provide formalin fixed, paraffin-embedded (FFPE) tumor tissue obtained from either a core or excisional tumor biopsy；\n* All female and male subjects of reproductive potential must agree to use an effective method of contraception, as determined by the Investigator, during and for 120 days after the last dose of study treatment；\n* Be able and willing to provide written informed consent and to comply with all requirements of study participation (including all study procedures).\n\nExclusion Criteria:\n\n* Histological or cytological pathology confirmed the presence of small cell carcinoma components, or the main component is squamous cell carcinoma；\n* Active malignancies within the past 3 years, with the exception of tumors in this study and cured local tumors；\n* Is currently participating in a study of an investigational agent or using an investigational device;\n* Active autoimmune disease requiring systemic treatment within 2 years prior to the start of study treatment；\n* Subjects who received any prior treatments targeting VEGFR;\n* Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA \\[qualitative\\] is detected);\n* History of myocardial infarction, unstable angina, cardiac or other vascular stenting, angioplasty, or surgery within 12 months prior to day 1 of study treatment;\n* Has undergone major surgery within 30 days prior to the first dose of study treatment;\n* Has an active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment NOTE: Subjects with vitiligo or resolved childhood asthma\u002Fatopy would be an exception to this rule. Subjects that require intermittent use of bronchodilators or local steroid injections would not be excluded from the study;\n* Has received a live virus vaccine within 30 days prior to first dose of study treatment；",{"count":632,"type":20},28,[52],"This is a phase II study. All patients are stage IV non-squamas non-small cell lung cancer(NSCLC) with malignant pleura effusion, Eastern Cooperative Oncology Group (ECOG) performance status 0-2. The purpose of this study is to evaluate the efficacy and safety of AK112 in combination with chemotherapy in patients with NSCLC with malignant pleura effusion.",[80],[196,637,638,639],"AK112","MPE","combination therapy","2025-01-09",{"date":642,"type":31},"2025-01-10",{"date":644,"type":20},"2025-02-01",{"date":114,"type":20},{"name":647,"class":38},"Sichuan University",{"id":649,"slug":650,"hasResults":12,"nctId":651,"briefTitle":652,"officialTitle":652,"acronym":4,"eligibilityCriteria":653,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":654,"enrollmentInfo":655,"targetDuration":4,"studyType":50,"phases":657,"briefSummary":658,"conditions":659,"keywords":660,"overallStatus":170,"whyStopped":4,"lastUpdateSubmitDate":665,"lastUpdatePostDateStruct":666,"startDateStruct":668,"completionDateStruct":670,"leadSponsor":672,"locationsCount":39},"100572911","the-diagnostic-value-of-bronchoscopic-needle-based-confocal-laser-endomicroscopy-ncle-as-a-real-time-detection-tool-for-diagnosing-peripheral-lung-cancer-a-multi-centre-randomised-controlled-trial-100572911","NCT06739421","The Diagnostic Value of Bronchoscopic Needle-based Confocal Laser Endomicroscopy (nCLE) As a Real-time Detection Tool for Diagnosing Peripheral Lung Cancer: a Multi-centre Randomised Controlled Trial","Inclusion Criteria:\n\n* patients with peripheral lung nodules suspected of lung cancer based on CT scan (10mm≤size\\\u003C30mm);\n* patients requiring diagnostic bronchoscopy procedure to determine the benign or malignant nature of the lung nodule;\n* Patients who can understand the purpose of the trial, participate voluntarily and sign an informed consent form.\n\nExclusion Criteria:\n\n* Inability or non-willingness to provide informed consent;\n* Endobronchial visible malignancy on bronchoscopic inspection;\n* Target lesion within reach of the linear EBUS scope;\n* Failure to comply with the study protocol;\n* Known allergy or risk factors for an allergic reaction to fluorescein;\n* Pregnancy or breast feeding;\n* Haemodynamic instability;\n* Refractory hypoxaemia;\n* Therapeutic anticoagulant use that cannot be withheld for an appropriate interval before the procedure;\n* Unable to tolerate general anaesthesia according to the anaesthesiologist;\n* Undergoing chemotherapy as several chemotherapies have fluorescent properties at the same wavelength (eg, doxorubicin).","90 Years",{"count":656,"type":20},1040,[159],"The goal of this prospective, multi-centre, randomised controlled clinical study is to evaluate the diagnostic efficacy and safety of nCLE guided lung biopsy in patients with for peripheral lung nodules under the assistance of navigation bronchoscopy (NB) and radial endobronchial ultrasound (rEBUS), and assess whether the biopsy techniques, namely transbronchial crybiopsy (TBCB) and transbronchial forceps biopsy (TBFB), would influence the diagnostic efficacy and safety of nCLE guided biopsy.\n\nParticipants will divided into nCLE-NB-rEBUS-forcep biopsy group, nCLE-NB-rEBUS-TBCB group, NB-rEBUS-forcep biopsy group, and NB-rEBUS-TBCB group at a 1:1:1:1 ratio by using central, computerized random sequence, and then undertake nCLE-NB-rEBUS-forcep biopsy, nCLE-NB-rEBUS-TBCB, NB-rEBUS-forcep biopsy, and NB-rEBUS-TBCB according to the group.\n\nResearchers will compare the diagnostic yield and incidence of adverse events of the four biopsy techniques.",[80,267],[661,662,663,664],"needle-based confocal laser endomicroscopy","peripheral lung cancer","peripheral lung nodules","lung biopsy","2024-12-17",{"date":667,"type":31},"2024-12-18",{"date":669,"type":20},"2025-01-01",{"date":671,"type":20},"2026-01-31",{"name":673,"class":38},"China-Japan Friendship Hospital"]